≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Increased muscle tone

EFO MESH Endpoint Browser PheWeb

INCREASEDMUSCLETONE

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — R29.0, R29.3
  • Hospital discharge: ICD-9 — 7817
  • Hospital discharge: ICD-8 — 78850
  • Cause of death: ICD-10 — R29.0, R29.3
  • Cause of death: ICD-9 — 7817
  • Cause of death: ICD-8 — 78850

2 out of 7 registries used, show all original rules.

103

4. Check minimum number of events

None

103

5. Include endpoints

275

6. Filter based on genotype QC (FinnGen only)

268

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Extra metadata

First used in FinnGen datafreeze
DF3

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 2783 1485 1289
Only index persons 2421 1322 1099
Unadjusted period prevalence (%)
Whole population 0.04 0.04 0.04
Only index persons 0.05 0.05 0.04
Median age at first event (years)
Whole population 25.36 29.73 20.19
Only index persons 27.32 31.23 22.61

-FinnGen-

Key figures

All Female Male
Number of individuals 268 176 92
Unadjusted period prevalence (%) 0.06 0.06 0.04
Median age at first event (years) 51.94 48.24 59.03

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
275
Matched controls
2750
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M62.4
ICD-10 Finland
Contracture of muscle
2229.9
203.4
172
*
R29.3
ICD-10 Finland
Abnormal posture
+∞
66.4
61
*
R29.0
ICD-10 Finland
Tetany
+∞
36.3
34
*
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
3.8
12.3
41
121
M79.6
ICD-10 Finland
Pain in limb
2.2
9.7
145
917
R4120
NOMESCO Finland
Occupational therapy
3.7
9.7
33
99
N03AX16
ATC
[U] pregabalin
2.5
9.5
76
368
ZXE05
NOMESCO Finland
Procedure duration 40 to 49 minutes
4.3
9.0
24
60
ZXE11
NOMESCO Finland
Procedure duration 60 to 89 minutes
3.7
8.8
29
85
78850
ICD-8 Finland
Other general symptoms, Tetany
+∞
8.4
8
*
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.1
8.4
122
752
WX702
NOMESCO Finland
Supraglottic ventilation device
3.7
8.0
26
75
Z3226
NOMESCO Finland
Physiotherapist
2.4
7.6
61
293
ZXE03
NOMESCO Finland
Procedure duration 20 to 29 minutes
3.8
7.5
23
64
A02BC02
ATC
pantoprazole; systemic
2.1
7.4
189
1406
M20.1
ICD-10 Finland
Hallux valgus (acquired)
3.0
7.1
32
114
TLC00
NOMESCO Finland
Insertion of intrauterine device
3.5
7.0
25
77
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
2.1
7.0
93
546
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
2.4
7.0
52
241
M25.5
ICD-10 Finland
Pain in joint
2.0
6.9
105
647
Z2221
NOMESCO Finland
Medical doctor
2.1
6.7
83
473
M19.0
ICD-10 Finland
Primary arthrosis of other joints
2.7
6.5
37
150
R4110
NOMESCO Finland
Physiotherapy
2.0
6.4
83
480
U07
ICPC
Urine symptom/complaint other
2.8
6.3
34
134
H11.3
ICD-10 Finland
Conjunctival haemorrhage
3.9
6.3
19
52
R2110
NOMESCO Finland
Giving the first information
3.5
6.3
22
67
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.4
6.3
48
225
M03BC51
ATC
orphenadrine, combinations; systemic
2.0
6.1
83
489
M72.2
ICD-10 Finland
Plantar fascial fibromatosis
2.8
6.0
31
119
M76.6
ICD-10 Finland
Achilles tendinitis
3.3
6.0
23
74

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Orthopedic Surgery
20 [38004465]
7.3e-01
1.1e+00
1.8e+00
1.0e+50
2.2e+00
1.5e+00
7.8e-01
cases:25.48%
controls:14.09%
cases:12.36%
controls:4.48%
cases:4.25%
controls:0.69%
cases:21.24%
controls:0.00%
cases:6.20%
controls:0.74%
cases:19.44%
controls:5.00%
cases:26.73%
controls:14.34%
66
365
193
2225
32
116
227
2474
11
18
248
2572
55
0
204
2590
16
19
242
2566
49
125
203
2375
58
313
159
1869
Outpatient Visit
OP [9202]
4.9e-01
4.9e-01
7.3e-01
4.8e+00
1.1e+00
6.5e-01
5.2e-01
cases:77.99%
controls:68.46%
cases:61.78%
controls:49.77%
cases:20.85%
controls:11.24%
cases:39.00%
controls:0.54%
cases:25.97%
controls:10.52%
cases:63.89%
controls:48.00%
cases:84.79%
controls:76.90%
202
1773
57
817
160
1289
99
1301
54
291
205
2299
101
14
158
2576
67
272
191
2313
161
1200
91
1300
184
1678
33
504
Neurology
13 [38004458]
6.8e-01
1.3e+00
9.3e-01
1.0e+50
2.4e+00
1.8e+00
1.2e+00
cases:13.51%
controls:7.34%
cases:10.42%
controls:3.05%
cases:2.70%
controls:1.08%
cases:11.58%
controls:0.00%
cases:5.81%
controls:0.58%
cases:15.08%
controls:2.96%
cases:23.04%
controls:8.30%
35
190
224
2400
27
79
232
2511
7
28
252
2562
30
0
229
2590
15
15
243
2570
38
74
214
2426
50
181
167
2001
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
R29.8 [45587505]
1.8e+00
—
—
—
—
2.5e+00
2.2e+00
cases:3.47%
controls:0.58%
—
—
—
—
—
—
—
—
cases:3.17%
controls:0.28%
cases:6.45%
controls:0.73%
9
15
250
2575
—
—
—
—
8
7
244
2493
14
16
203
2166
Supplier / Service Provider
OMOP5117446 [33004]
-4.2e-01
-7.4e-01
—
—
—
2.9e+00
3.5e+00
cases:15.83%
controls:22.20%
cases:4.25%
controls:8.53%
—
—
—
—
—
—
cases:4.37%
controls:0.24%
cases:17.05%
controls:0.64%
41
575
218
2015
11
221
248
2369
—
—
—
11
6
241
2494
37
14
180
2168
Other healthcare associate professional
Z3229 [2001311561]
1.9e+00
2.1e+00
—
—
—
2.3e+00
1.6e+00
cases:3.47%
controls:0.54%
cases:2.70%
controls:0.35%
—
—
—
—
—
—
cases:2.78%
controls:0.28%
cases:3.69%
controls:0.78%
9
14
250
2576
7
9
252
2581
—
—
—
7
7
245
2493
8
17
209
2165
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
2.0e-01
5.7e-01
1.1e+00
3.1e+00
8.3e-01
6.8e-01
2.8e-01
cases:28.57%
controls:24.63%
cases:29.73%
controls:19.31%
cases:8.49%
controls:3.09%
cases:4.25%
controls:0.19%
cases:9.30%
controls:4.29%
cases:32.14%
controls:19.40%
cases:43.32%
controls:36.71%
74
638
185
1952
77
500
182
2090
22
80
237
2510
11
5
248
2585
24
111
234
2474
81
485
171
2015
94
801
123
1381
General Practice
1 [38004446]
8.9e-01
1.1e+00
1.7e+00
1.0e+50
2.2e+00
1.2e+00
7.9e-01
cases:22.78%
controls:10.77%
cases:11.58%
controls:4.09%
cases:2.70%
controls:0.50%
cases:14.67%
controls:0.00%
cases:3.88%
controls:0.46%
cases:14.68%
controls:4.92%
cases:22.58%
controls:11.64%
59
279
200
2311
30
106
229
2484
7
13
252
2577
38
0
221
2590
10
12
248
2573
37
123
215
2377
49
254
168
1928
Physiotherapy
R4110 [2001310233]
1.0e+00
1.2e+00
—
1.0e+50
—
1.6e+00
1.6e+00
cases:10.04%
controls:3.90%
cases:5.02%
controls:1.58%
—
—
cases:2.32%
controls:0.00%
—
—
cases:6.35%
controls:1.36%
cases:11.52%
controls:2.47%
26
101
233
2489
13
41
246
2549
—
6
0
253
2590
—
16
34
236
2466
25
54
192
2128
Otolaryngology
4 [38004449]
6.3e-01
9.3e-01
—
—
2.4e+00
1.3e+00
5.1e-01
cases:17.37%
controls:10.04%
cases:8.11%
controls:3.36%
—
—
—
—
cases:5.43%
controls:0.50%
cases:10.71%
controls:3.24%
cases:15.21%
controls:9.72%
45
260
214
2330
21
87
238
2503
—
—
14
13
244
2572
27
81
225
2419
33
212
184
1970
etoricoxib; oral
M01AH05 [21603996]
6.2e-01
8.6e-01
1.9e+00
—
1.3e+00
9.4e-01
6.8e-01
cases:21.24%
controls:12.70%
cases:10.81%
controls:4.86%
cases:3.09%
controls:0.46%
—
—
cases:2.33%
controls:0.62%
cases:10.71%
controls:4.48%
cases:24.88%
controls:14.39%
55
329
204
2261
28
126
231
2464
8
12
251
2578
—
6
16
252
2569
27
112
225
2388
54
314
163
1868
MCH [Entitic mass]
28539-5 [3035941]
8.4e-02
4.5e-01
7.3e-01
3.0e+00
7.3e-01
5.3e-01
2.3e-01
cases:35.14%
controls:33.24%
cases:37.84%
controls:27.88%
cases:9.65%
controls:4.90%
cases:5.02%
controls:0.27%
cases:11.24%
controls:5.76%
cases:40.48%
controls:28.64%
cases:54.38%
controls:48.63%
91
861
168
1729
98
722
161
1868
25
127
234
2463
13
7
246
2583
29
149
229
2436
102
716
150
1784
118
1061
99
1121
Neck symptom/complaint
L01 [2002000626]
1.3e+00
—
—
—
—
2.0e+00
1.3e+00
cases:5.79%
controls:1.70%
—
—
—
—
—
—
—
—
cases:2.38%
controls:0.32%
cases:6.45%
controls:1.92%
15
44
244
2546
—
—
—
—
6
8
246
2492
14
42
203
2140
Case Management Agency
251B00000X [38004193]
2.3e-01
3.1e-01
6.1e-01
3.2e+00
6.8e-01
2.9e-01
1.5e-01
cases:64.86%
controls:59.46%
cases:60.62%
controls:53.01%
cases:31.27%
controls:19.81%
cases:28.19%
controls:1.51%
cases:34.11%
controls:20.85%
cases:61.11%
controls:54.04%
cases:74.19%
controls:71.31%
168
1540
91
1050
157
1373
102
1217
81
513
178
2077
73
39
186
2551
88
539
170
2046
154
1351
98
1149
161
1556
56
626
Emergency Room Visit
ER [9203]
4.5e-01
8.5e-01
1.0e+00
1.0e+50
1.7e+00
8.2e-01
6.0e-01
cases:40.54%
controls:30.23%
cases:21.62%
controls:10.50%
cases:3.47%
controls:1.31%
cases:25.48%
controls:0.00%
cases:7.36%
controls:1.43%
cases:20.63%
controls:10.28%
cases:41.94%
controls:28.37%
105
783
154
1807
56
272
203
2318
9
34
250
2556
66
0
193
2590
19
37
239
2548
52
257
200
2243
91
619
126
1563
orphenadrine (citrate); oral, parenteral
M03BC01 [21604112]
5.6e-01
8.2e-01
—
—
2.1e+00
1.5e+00
8.7e-01
cases:11.58%
controls:6.99%
cases:5.02%
controls:2.28%
—
—
—
—
cases:2.71%
controls:0.35%
cases:6.75%
controls:1.64%
cases:14.75%
controls:6.74%
30
181
229
2409
13
59
246
2531
—
—
7
9
251
2576
17
41
235
2459
32
147
185
2035
orphenadrine (chloride); oral, parenteral
N04AB02 [21604458]
5.6e-01
8.2e-01
—
—
2.1e+00
1.5e+00
8.7e-01
cases:11.58%
controls:6.99%
cases:5.02%
controls:2.28%
—
—
—
—
cases:2.71%
controls:0.35%
cases:6.75%
controls:1.64%
cases:14.75%
controls:6.74%
30
181
229
2409
13
59
246
2531
—
—
7
9
251
2576
17
41
235
2459
32
147
185
2035
Hallux valgus (acquired)
M20.1 [45606152]
1.2e+00
1.7e+00
—
1.0e+50
—
2.6e+00
1.8e+00
cases:3.47%
controls:1.04%
cases:1.93%
controls:0.35%
—
—
cases:5.79%
controls:0.00%
—
—
cases:3.57%
controls:0.28%
cases:4.15%
controls:0.69%
9
27
250
2563
5
9
254
2581
—
15
0
244
2590
—
9
7
243
2493
9
15
208
2167
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
3.1e-01
5.4e-01
8.7e-01
3.2e+00
8.2e-01
5.2e-01
4.8e-01
cases:26.25%
controls:20.73%
cases:26.64%
controls:17.45%
cases:6.56%
controls:2.86%
cases:4.63%
controls:0.19%
cases:7.75%
controls:3.56%
cases:27.38%
controls:18.32%
cases:42.86%
controls:31.62%
68
537
191
2053
69
452
190
2138
17
74
242
2516
12
5
247
2585
20
92
238
2493
69
458
183
2042
93
690
124
1492
Platelets [#/volume] in Blood
26515-7 [3007461]
8.4e-02
4.5e-01
7.3e-01
3.0e+00
7.7e-01
5.3e-01
2.4e-01
cases:35.14%
controls:33.24%
cases:37.84%
controls:27.95%
cases:9.65%
controls:4.90%
cases:5.02%
controls:0.27%
cases:11.63%
controls:5.76%
cases:40.48%
controls:28.60%
cases:54.38%
controls:48.44%
91
861
168
1729
98
724
161
1866
25
127
234
2463
13
7
246
2583
30
149
228
2436
102
715
150
1785
118
1057
99
1125
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
8.2e-02
4.5e-01
7.3e-01
3.0e+00
7.7e-01
5.3e-01
2.3e-01
cases:35.14%
controls:33.28%
cases:37.84%
controls:27.95%
cases:9.65%
controls:4.90%
cases:5.02%
controls:0.27%
cases:11.63%
controls:5.76%
cases:40.48%
controls:28.68%
cases:54.38%
controls:48.67%
91
862
168
1728
98
724
161
1866
25
127
234
2463
13
7
246
2583
30
149
228
2436
102
717
150
1783
118
1062
99
1120
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
8.1e-02
4.5e-01
7.2e-01
3.0e+00
7.7e-01
5.2e-01
2.3e-01
cases:35.14%
controls:33.32%
cases:37.84%
controls:27.92%
cases:9.65%
controls:4.94%
cases:5.02%
controls:0.27%
cases:11.63%
controls:5.76%
cases:40.48%
controls:28.72%
cases:54.38%
controls:48.76%
91
863
168
1727
98
723
161
1867
25
128
234
2462
13
7
246
2583
30
149
228
2436
102
718
150
1782
118
1064
99
1118
Leukocytes [#/volume] in Blood
26464-8 [3010813]
8.1e-02
4.5e-01
7.2e-01
3.0e+00
7.7e-01
5.2e-01
2.3e-01
cases:35.14%
controls:33.32%
cases:37.84%
controls:27.99%
cases:9.65%
controls:4.94%
cases:5.02%
controls:0.27%
cases:11.63%
controls:5.76%
cases:40.48%
controls:28.72%
cases:54.38%
controls:48.67%
91
863
168
1727
98
725
161
1865
25
128
234
2462
13
7
246
2583
30
149
228
2436
102
718
150
1782
118
1062
99
1120
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
8.2e-02
4.5e-01
7.3e-01
3.0e+00
7.3e-01
5.3e-01
2.3e-01
cases:35.14%
controls:33.28%
cases:37.84%
controls:27.95%
cases:9.65%
controls:4.90%
cases:5.02%
controls:0.27%
cases:11.24%
controls:5.76%
cases:40.48%
controls:28.68%
cases:54.38%
controls:48.67%
91
862
168
1728
98
724
161
1866
25
127
234
2463
13
7
246
2583
29
149
229
2436
102
717
150
1783
118
1062
99
1120
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
8.2e-02
4.5e-01
7.3e-01
3.0e+00
7.3e-01
5.3e-01
2.3e-01
cases:35.14%
controls:33.28%
cases:37.84%
controls:27.95%
cases:9.65%
controls:4.90%
cases:5.02%
controls:0.27%
cases:11.24%
controls:5.76%
cases:40.48%
controls:28.68%
cases:54.38%
controls:48.67%
91
862
168
1728
98
724
161
1866
25
127
234
2463
13
7
246
2583
29
149
229
2436
102
717
150
1783
118
1062
99
1120
CBC panel - Blood by Automated count
58410-2 [40761511]
1.4e-01
4.8e-01
1.1e+00
3.1e+00
8.6e-01
4.7e-01
2.8e-01
cases:30.89%
controls:28.03%
cases:27.80%
controls:19.31%
cases:7.34%
controls:2.63%
cases:4.25%
controls:0.19%
cases:7.36%
controls:3.25%
cases:28.17%
controls:19.72%
cases:46.08%
controls:39.32%
80
726
179
1864
72
500
187
2090
19
68
240
2522
11
5
248
2585
19
84
239
2501
71
493
181
2007
100
858
117
1324
Protein [Presence] in Urine by Test strip
20454-5 [3014051]
3.7e-01
4.4e-01
—
—
2.3e+00
1.1e+00
7.4e-01
cases:5.79%
controls:4.05%
cases:3.86%
controls:2.51%
—
—
—
—
cases:2.71%
controls:0.27%
cases:6.75%
controls:2.44%
cases:14.75%
controls:7.61%
15
105
244
2485
10
65
249
2525
—
—
7
7
251
2578
17
61
235
2439
32
166
185
2016
Laboratory Visit
OMOP4822461 [32036]
1.3e-01
4.1e-01
4.5e-01
2.8e+00
7.2e-01
4.7e-01
7.6e-02
cases:39.77%
controls:36.80%
cases:44.79%
controls:34.90%
cases:15.06%
controls:10.15%
cases:8.49%
controls:0.58%
cases:19.38%
controls:10.48%
cases:47.22%
controls:35.76%
cases:56.22%
controls:54.35%
103
953
156
1637
116
904
143
1686
39
263
220
2327
22
15
237
2575
50
271
208
2314
119
894
133
1606
122
1186
95
996
Scheduled procedure
ZXD10 [2001311387]
8.0e-01
3.2e-01
—
—
—
1.8e+00
1.3e+00
cases:10.42%
controls:4.98%
cases:2.32%
controls:1.70%
—
—
—
—
—
—
cases:5.56%
controls:1.00%
cases:9.22%
controls:2.75%
27
129
232
2461
6
44
253
2546
—
—
—
14
25
238
2475
20
60
197
2122
Internal Medicine
11 [38004456]
5.3e-01
1.0e+00
1.5e+00
—
9.7e-01
6.3e-01
6.1e-01
cases:28.57%
controls:19.11%
cases:17.76%
controls:7.26%
cases:3.86%
controls:0.89%
—
—
cases:2.71%
controls:1.04%
cases:13.10%
controls:7.40%
cases:29.95%
controls:18.79%
74
495
185
2095
46
188
213
2402
10
23
249
2567
—
7
27
251
2558
33
185
219
2315
65
410
152
1772
Pharmacy visit
OMOP4822462 [581458]
3.3e-01
4.7e-01
5.7e-01
1.7e+00
5.9e-01
7.3e-01
8.8e-01
cases:94.98%
controls:93.13%
cases:87.26%
controls:81.00%
cases:56.37%
controls:42.16%
cases:11.97%
controls:2.47%
cases:56.98%
controls:42.40%
cases:90.08%
controls:81.40%
cases:97.70%
controls:94.64%
246
2412
13
178
226
2098
33
492
146
1092
113
1498
31
64
228
2526
147
1096
111
1489
227
2035
25
465
212
2065
5
117
naproxcinod
M01AE18 [40254094]
6.2e-01
3.3e-01
—
—
2.0e+00
8.8e-01
9.1e-01
cases:16.99%
controls:9.96%
cases:4.63%
controls:3.36%
—
—
—
—
cases:2.33%
controls:0.31%
cases:7.14%
controls:3.08%
cases:19.35%
controls:8.80%
44
258
215
2332
12
87
247
2503
—
—
6
8
252
2577
18
77
234
2423
42
192
175
1990
naproxen; oral, rectal
M01AE02 [21603968]
6.2e-01
3.3e-01
—
—
2.0e+00
8.8e-01
9.1e-01
cases:16.99%
controls:9.96%
cases:4.63%
controls:3.36%
—
—
—
—
cases:2.33%
controls:0.31%
cases:7.14%
controls:3.08%
cases:19.35%
controls:8.80%
44
258
215
2332
12
87
247
2503
—
—
6
8
252
2577
18
77
234
2423
42
192
175
1990
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
2.9e-01
4.8e-01
—
—
1.7e+00
9.5e-01
7.7e-01
cases:17.37%
controls:13.59%
cases:9.65%
controls:6.18%
—
—
—
—
cases:3.88%
controls:0.74%
cases:15.48%
controls:6.60%
cases:31.34%
controls:17.51%
45
352
214
2238
25
160
234
2430
—
—
10
19
248
2566
39
165
213
2335
68
382
149
1800
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
3.6e-01
4.9e-01
—
—
1.6e+00
8.5e-01
7.9e-01
cases:19.31%
controls:14.25%
cases:10.04%
controls:6.41%
—
—
—
—
cases:4.26%
controls:0.89%
cases:14.68%
controls:6.84%
cases:33.64%
controls:18.65%
50
369
209
2221
26
166
233
2424
—
—
11
23
247
2562
37
171
215
2329
73
407
144
1775
Primary arthrosis of other joints
M19.0 [45601353]
1.4e+00
—
—
—
—
—
1.7e+00
cases:3.86%
controls:0.97%
—
—
—
—
—
—
—
—
—
—
cases:5.07%
controls:0.96%
10
25
249
2565
—
—
—
—
—
11
21
206
2161
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
-3.1e-01
1.0e+00
—
—
—
1.2e+00
8.4e-01
cases:3.86%
controls:5.21%
cases:6.18%
controls:2.32%
—
—
—
—
—
—
cases:7.54%
controls:2.32%
cases:17.51%
controls:8.43%
10
135
249
2455
16
60
243
2530
—
—
—
19
58
233
2442
38
184
179
1998
More than one and less than three hours
ZXE10 [2001311401]
5.3e-01
4.8e-01
—
—
—
1.5e+00
1.6e+00
cases:8.49%
controls:5.17%
cases:3.09%
controls:1.93%
—
—
—
—
—
—
cases:5.56%
controls:1.32%
cases:9.22%
controls:2.02%
22
134
237
2456
8
50
251
2540
—
—
—
14
33
238
2467
20
44
197
2138
Physiotherapist
Z3226 [2001311560]
1.5e+00
1.2e+00
—
1.0e+50
—
1.8e+00
1.6e+00
cases:6.95%
controls:1.70%
cases:2.70%
controls:0.81%
—
—
cases:1.93%
controls:0.00%
—
—
cases:2.38%
controls:0.40%
cases:5.07%
controls:1.10%
18
44
241
2546
7
21
252
2569
—
5
0
254
2590
—
6
10
246
2490
11
24
206
2158
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
1.4e-01
3.4e-01
7.5e-01
3.0e+00
6.6e-01
4.5e-01
3.9e-01
cases:31.66%
controls:28.69%
cases:27.80%
controls:21.51%
cases:6.95%
controls:3.40%
cases:5.02%
controls:0.27%
cases:6.59%
controls:3.52%
cases:30.56%
controls:21.96%
cases:49.31%
controls:39.83%
82
743
177
1847
72
557
187
2033
18
88
241
2502
13
7
246
2583
17
91
241
2494
77
549
175
1951
107
869
110
1313
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
8.6e-02
3.6e-01
7.4e-01
3.0e+00
6.7e-01
4.2e-01
3.8e-01
cases:30.12%
controls:28.34%
cases:27.80%
controls:21.12%
cases:6.56%
controls:3.24%
cases:5.02%
controls:0.27%
cases:6.59%
controls:3.48%
cases:29.76%
controls:21.84%
cases:48.85%
controls:39.55%
78
734
181
1856
72
547
187
2043
17
84
242
2506
13
7
246
2583
17
90
241
2495
75
546
177
1954
106
863
111
1319
Office Visit
OMOP4822458 [581477]
-1.5e-02
8.1e-01
—
—
2.8e+00
8.6e-01
3.9e-01
cases:8.49%
controls:8.61%
cases:6.18%
controls:2.86%
—
—
—
—
cases:3.88%
controls:0.23%
cases:6.35%
controls:2.80%
cases:11.06%
controls:7.79%
22
223
237
2367
16
74
243
2516
—
—
10
6
248
2579
16
70
236
2430
24
170
193
2012
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
7.7e-02
2.7e-01
6.6e-01
2.7e+00
4.8e-01
4.3e-01
3.6e-01
cases:32.43%
controls:30.77%
cases:30.12%
controls:24.75%
cases:7.72%
controls:4.13%
cases:5.02%
controls:0.35%
cases:7.36%
controls:4.68%
cases:34.52%
controls:25.52%
cases:53.00%
controls:43.95%
84
797
175
1793
78
641
181
1949
20
107
239
2483
13
9
246
2581
19
121
239
2464
87
638
165
1862
115
959
102
1223
Spinalanesthesia
WX320 [2001310799]
7.4e-01
—
—
—
—
1.6e+00
1.1e+00
cases:5.41%
controls:2.66%
—
—
—
—
—
—
—
—
cases:3.97%
controls:0.84%
cases:6.45%
controls:2.29%
14
69
245
2521
—
—
—
—
10
21
242
2479
14
50
203
2132
Pain in joint
M25.5 [45586941]
5.0e-01
1.4e+00
—
1.0e+50
—
1.2e+00
7.5e-01
cases:6.18%
controls:3.82%
cases:5.41%
controls:1.43%
—
—
cases:1.93%
controls:0.00%
—
—
cases:4.76%
controls:1.44%
cases:12.44%
controls:6.28%
16
99
243
2491
14
37
245
2553
—
5
0
254
2590
—
12
36
240
2464
27
137
190
2045
Troponin I.cardiac [Mass/volume] in Serum or Plasma
10839-9 [3021337]
3.3e-01
1.0e+00
—
1.0e+50
—
1.5e+00
1.1e+00
cases:3.86%
controls:2.82%
cases:3.47%
controls:1.31%
—
—
cases:1.93%
controls:0.00%
—
—
cases:5.16%
controls:1.24%
cases:10.14%
controls:3.62%
10
73
249
2517
9
34
250
2556
—
5
0
254
2590
—
13
31
239
2469
22
79
195
2103
Medical doctor
Z2221 [2001311556]
1.1e+00
1.3e+00
—
—
—
1.4e+00
1.5e+00
cases:11.20%
controls:4.13%
cases:3.86%
controls:1.04%
—
—
—
—
—
—
cases:3.57%
controls:0.88%
cases:9.68%
controls:2.43%
29
107
230
2483
10
27
249
2563
—
—
—
9
22
243
2478
21
53
196
2129
Inpatient Hospital
21 [8717]
2.2e-01
7.0e-01
1.0e+00
1.0e+50
1.8e+00
5.6e-01
4.4e-01
cases:33.98%
controls:29.27%
cases:16.60%
controls:9.03%
cases:3.09%
controls:1.12%
cases:6.95%
controls:0.00%
cases:6.20%
controls:1.04%
cases:13.89%
controls:8.44%
cases:29.95%
controls:21.59%
88
758
171
1832
43
234
216
2356
8
29
251
2561
18
0
241
2590
16
27
242
2558
35
211
217
2289
65
471
152
1711
Fungus identified in Specimen by Culture
580-1 [3000494]
2.3e-01
2.5e+00
—
—
—
—
8.9e-01
cases:2.32%
controls:1.85%
cases:2.32%
controls:0.19%
—
—
—
—
—
—
—
—
cases:5.07%
controls:2.15%
6
48
253
2542
6
5
253
2585
—
—
—
—
11
47
206
2135
Adjustment or review of hearing aid
DAX00 [2001301528]
-1.0e+50
—
—
—
—
—
2.5e+00
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
cases:3.23%
controls:0.27%
0
7
259
2583
—
—
—
—
—
7
6
210
2176
Metatarsalgia
M77.4 [45601544]
—
—
—
1.0e+50
—
2.5e+00
—
—
—
—
—
—
—
cases:3.47%
controls:0.00%
—
—
cases:2.78%
controls:0.24%
—
—
—
—
—
9
0
250
2590
—
7
6
245
2494
—
Procedure duration 60 to 89 minutes
ZXE11 [2001311402]
—
—
—
—
—
2.0e+00
2.4e+00
—
—
—
—
—
—
—
—
—
—
cases:1.98%
controls:0.28%
cases:5.07%
controls:0.46%
—
—
—
—
—
5
7
247
2493
11
10
206
2172
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
1.2e-01
9.0e-01
—
—
2.3e+00
1.4e+00
1.0e+00
cases:4.63%
controls:4.13%
cases:4.25%
controls:1.78%
—
—
—
—
cases:1.94%
controls:0.19%
cases:4.76%
controls:1.20%
cases:14.75%
controls:6.00%
12
107
247
2483
11
46
248
2544
—
—
5
5
253
2580
12
30
240
2470
32
131
185
2051
Hospital outpatient
ZY010 [2001311599]
—
—
—
—
—
1.8e+00
2.4e+00
—
—
—
—
—
—
—
—
—
—
cases:1.98%
controls:0.32%
cases:5.07%
controls:0.50%
—
—
—
—
—
5
8
247
2492
11
11
206
2171
Polyarthrosis, unspecified
M15.9 [45543481]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.15%
controls:0.41%
—
—
—
—
—
—
9
9
208
2173
Procedure duration 50 to 59 minutes
ZXE06 [2001311400]
1.5e+00
—
—
—
—
—
2.3e+00
cases:1.93%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
cases:3.69%
controls:0.37%
5
11
254
2579
—
—
—
—
—
8
8
209
2174
aciclovir
D06BB03 [21602085]
2.3e+00
—
—
—
—
—
—
cases:3.09%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
—
—
8
8
251
2582
—
—
—
—
—
—
Poisoning by systemic antibiotics
T36 [45756588]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.30%
controls:0.23%
—
—
—
—
—
—
5
5
212
2177
Written specialist consultation based on a referral from a dentist or a physician
WZC10 [2001310887]
2.3e+00
—
—
—
—
—
—
cases:2.70%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
7
7
252
2583
—
—
—
—
—
—
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
2.7e-01
4.2e-01
8.0e-01
—
1.0e+00
7.3e-01
5.3e-01
cases:30.50%
controls:25.10%
cases:24.32%
controls:17.49%
cases:5.02%
controls:2.32%
—
—
cases:7.36%
controls:2.75%
cases:28.57%
controls:16.16%
cases:48.85%
controls:36.02%
79
650
180
1940
63
453
196
2137
13
60
246
2530
—
19
71
239
2514
72
404
180
2096
106
786
111
1396
Physical Medicine And Rehabilitation
25 [38004468]
3.3e-01
1.0e+00
1.8e+00
—
1.7e+00
1.3e+00
6.8e-01
cases:9.27%
controls:6.83%
cases:6.56%
controls:2.51%
cases:1.93%
controls:0.31%
—
—
cases:2.33%
controls:0.43%
cases:8.33%
controls:2.48%
cases:11.98%
controls:6.46%
24
177
235
2413
17
65
242
2525
5
8
254
2582
—
6
11
252
2574
21
62
231
2438
26
141
191
2041
fluconazole; oral, parenteral
J02AC01 [21603080]
9.4e-01
1.3e+00
—
—
—
2.2e-01
6.3e-01
cases:13.13%
controls:5.60%
cases:6.18%
controls:1.74%
—
—
—
—
—
—
cases:1.98%
controls:1.60%
cases:10.60%
controls:5.96%
34
145
225
2445
16
45
243
2545
—
—
—
5
40
247
2460
23
130
194
2052
Social worker
Z2446 [2001311559]
—
—
—
—
—
-1.0e+50
2.2e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
cases:3.69%
controls:0.41%
—
—
—
—
—
0
5
252
2495
8
9
209
2173
Chronic maxillary sinusitis
J32.0 [45586667]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.69%
controls:0.41%
—
—
—
—
—
—
8
9
209
2173
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
2.3e-01
7.8e-01
—
—
1.3e+00
7.0e-01
7.4e-01
cases:19.69%
controls:16.37%
cases:17.37%
controls:8.80%
—
—
—
—
cases:3.49%
controls:1.01%
cases:15.87%
controls:8.56%
cases:35.94%
controls:21.13%
51
424
208
2166
45
228
214
2362
—
—
9
26
249
2559
40
214
212
2286
78
461
139
1721
Procedure duration 10 to 19 minutes
ZXE02 [2001311396]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.23%
controls:0.37%
—
—
—
—
—
—
7
8
210
2174
Pain in limb
M79.6 [45587063]
7.3e-01
6.4e-01
—
—
—
1.3e+00
8.9e-01
cases:10.42%
controls:5.33%
cases:4.25%
controls:2.28%
—
—
—
—
—
—
cases:7.94%
controls:2.28%
cases:17.51%
controls:8.02%
27
138
232
2452
11
59
248
2531
—
—
—
20
57
232
2443
38
175
179
2007
pantoprazole; oral, parenteral
A02BC02 [21600097]
5.6e-01
3.9e-01
5.0e-01
—
8.7e-01
8.1e-01
7.6e-01
cases:23.55%
controls:15.02%
cases:11.97%
controls:8.42%
cases:2.70%
controls:1.66%
—
—
cases:4.65%
controls:2.01%
cases:17.46%
controls:8.64%
cases:31.34%
controls:17.64%
61
389
198
2201
31
218
228
2372
7
43
252
2547
—
12
52
246
2533
44
216
208
2284
68
385
149
1797
Plantar fascial fibromatosis
M72.2 [45553265]
1.2e+00
—
—
1.0e+50
—
1.8e+00
2.1e+00
cases:2.32%
controls:0.73%
—
—
—
—
cases:5.41%
controls:0.00%
—
—
cases:1.98%
controls:0.32%
cases:4.61%
controls:0.60%
6
19
253
2571
—
—
14
0
245
2590
—
5
8
247
2492
10
13
207
2169
Insertion of intrauterine device
TLC00 [2001306647]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.23%
controls:0.41%
—
—
—
—
—
—
7
9
210
2173
Yersinia sp identified in Stool by Organism specific culture
28549-4 [3014765]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.23%
controls:0.41%
—
—
—
—
—
—
7
9
210
2173
Shigella sp [Presence] in Stool by Culture
82300-5 [42529406]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.23%
controls:0.41%
—
—
—
—
—
—
7
9
210
2173
Campylobacter sp identified in Tissue by Organism specific culture
20740-7 [3006418]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.23%
controls:0.41%
—
—
—
—
—
—
7
9
210
2173
Open wound of scalp
S01.0 [45592468]
—
—
—
—
—
-1.0e+50
2.0e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.28%
cases:2.76%
controls:0.37%
—
—
—
—
—
0
7
252
2493
6
8
211
2174
Benign neoplasm: Sigmoid colon
D12.5 [45552326]
—
—
—
—
—
-1.0e+50
2.0e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
cases:2.76%
controls:0.37%
—
—
—
—
—
0
5
252
2495
6
8
211
2174
Impacted cerumen
H61.2 [45562307]
2.0e+00
—
—
—
—
—
-1.0e+50
cases:2.32%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
6
8
253
2582
—
—
—
—
—
0
18
217
2164
General Surgery
2 [38004447]
5.0e-01
8.9e-01
1.3e+00
—
1.7e+00
1.1e+00
5.9e-01
cases:22.78%
controls:15.21%
cases:11.20%
controls:4.90%
cases:1.93%
controls:0.54%
—
—
cases:2.71%
controls:0.50%
cases:11.90%
controls:4.24%
cases:19.82%
controls:12.10%
59
394
200
2196
29
127
230
2463
5
14
254
2576
—
7
13
251
2572
30
106
222
2394
43
264
174
1918
hydrocortisone
D07XA01 [21602180]
2.5e-01
2.0e+00
—
—
—
—
5.3e-01
cases:2.32%
controls:1.81%
cases:3.47%
controls:0.50%
—
—
—
—
—
—
—
—
cases:3.69%
controls:2.20%
6
47
253
2543
9
13
250
2577
—
—
—
—
8
48
209
2134
chlorhexidine
S02AA09 [21605155]
2.5e-01
2.0e+00
—
—
—
—
5.3e-01
cases:2.32%
controls:1.81%
cases:3.47%
controls:0.50%
—
—
—
—
—
—
—
—
cases:3.69%
controls:2.20%
6
47
253
2543
9
13
250
2577
—
—
—
—
8
48
209
2134
triamcinolone and antiseptics
D07BB03 [21602150]
2.3e-01
2.0e+00
—
—
—
—
5.3e-01
cases:2.32%
controls:1.85%
cases:3.47%
controls:0.50%
—
—
—
—
—
—
—
—
cases:3.69%
controls:2.20%
6
48
253
2542
9
13
250
2577
—
—
—
—
8
48
209
2134
chlorhexidine
D09AA12 [21602275]
2.5e-01
2.0e+00
—
—
—
—
5.3e-01
cases:2.32%
controls:1.81%
cases:3.47%
controls:0.50%
—
—
—
—
—
—
—
—
cases:3.69%
controls:2.20%
6
47
253
2543
9
13
250
2577
—
—
—
—
8
48
209
2134
other antifungals for topical use - combinations; ointment
D01AE20 [21601959]
2.5e-01
2.0e+00
—
—
—
—
5.3e-01
cases:2.32%
controls:1.81%
cases:3.47%
controls:0.50%
—
—
—
—
—
—
—
—
cases:3.69%
controls:2.20%
6
47
253
2543
9
13
250
2577
—
—
—
—
8
48
209
2134
chlorhexidine
S03AA04 [21605193]
2.5e-01
2.0e+00
—
—
—
—
5.3e-01
cases:2.32%
controls:1.81%
cases:3.47%
controls:0.50%
—
—
—
—
—
—
—
—
cases:3.69%
controls:2.20%
6
47
253
2543
9
13
250
2577
—
—
—
—
8
48
209
2134
chlorhexidine, combinations
D08AC52 [21602208]
2.5e-01
2.0e+00
—
—
—
—
5.3e-01
cases:2.32%
controls:1.81%
cases:3.47%
controls:0.50%
—
—
—
—
—
—
—
—
cases:3.69%
controls:2.20%
6
47
253
2543
9
13
250
2577
—
—
—
—
8
48
209
2134
hydrocortisone and antiseptics
D07BA04 [21602146]
2.5e-01
2.0e+00
—
—
—
—
5.3e-01
cases:2.32%
controls:1.81%
cases:3.47%
controls:0.50%
—
—
—
—
—
—
—
—
cases:3.69%
controls:2.20%
6
47
253
2543
9
13
250
2577
—
—
—
—
8
48
209
2134
Leukocytes [#/volume] in Urine
30405-5 [3018095]
2.7e-01
7.6e-01
—
—
—
1.1e+00
8.4e-01
cases:7.34%
controls:5.68%
cases:6.56%
controls:3.17%
—
—
—
—
—
—
cases:9.52%
controls:3.36%
cases:19.35%
controls:9.40%
19
147
240
2443
17
82
242
2508
—
—
—
24
84
228
2416
42
205
175
1977
Supraglottic ventilation device
WX702 [2001310818]
1.3e+00
—
—
—
—
—
1.9e+00
cases:1.93%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
cases:3.69%
controls:0.55%
5
14
254
2576
—
—
—
—
—
8
12
209
2170
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
1.9e-01
6.6e-01
—
—
—
1.0e+00
8.8e-01
cases:6.95%
controls:5.79%
cases:5.41%
controls:2.86%
—
—
—
—
—
—
cases:7.14%
controls:2.68%
cases:17.97%
controls:8.34%
18
150
241
2440
14
74
245
2516
—
—
—
18
67
234
2433
39
182
178
2000
itraconazole; oral, parenteral
J02AC02 [21603081]
9.7e-01
—
—
—
—
—
1.9e+00
cases:2.70%
controls:1.04%
—
—
—
—
—
—
—
—
—
—
cases:4.15%
controls:0.64%
7
27
252
2563
—
—
—
—
—
9
14
208
2168
Oral Surgery
19 [38004464]
1.7e+00
-1.0e+50
—
—
—
-1.0e+50
1.9e+00
cases:2.32%
controls:0.42%
cases:0.00%
controls:0.35%
—
—
—
—
—
—
cases:0.00%
controls:0.40%
cases:4.15%
controls:0.64%
6
11
253
2579
0
9
259
2581
—
—
—
0
10
252
2490
9
14
208
2168
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
2.0e-01
7.4e-01
—
—
—
1.1e+00
8.4e-01
cases:5.79%
controls:4.79%
cases:5.02%
controls:2.47%
—
—
—
—
—
—
cases:7.54%
controls:2.76%
cases:16.59%
controls:7.88%
15
124
244
2466
13
64
246
2526
—
—
—
19
69
233
2431
36
172
181
2010
Streptococcus pyogenes Ag [Presence] in Throat
18481-2 [3033319]
2.0e-01
1.9e+00
—
—
—
—
1.5e-01
cases:1.93%
controls:1.58%
cases:2.70%
controls:0.42%
—
—
—
—
—
—
—
—
cases:2.76%
controls:2.38%
5
41
254
2549
7
11
252
2579
—
—
—
—
6
52
211
2130
Neurosurgery
14 [38004459]
-9.7e-02
1.9e+00
—
—
—
—
1.5e-01
cases:1.93%
controls:2.12%
cases:3.86%
controls:0.62%
—
—
—
—
—
—
—
—
cases:2.76%
controls:2.38%
5
55
254
2535
10
16
249
2574
—
—
—
—
6
52
211
2130
clindamycin; vaginal
G01AA10 [21602372]
4.4e-01
1.8e+00
—
—
—
—
6.7e-01
cases:3.09%
controls:2.01%
cases:2.70%
controls:0.46%
—
—
—
—
—
—
—
—
cases:3.69%
controls:1.92%
8
52
251
2538
7
12
252
2578
—
—
—
—
8
42
209
2140
Urinary frequency/urgency
U02 [2002001138]
5.6e-01
1.8e+00
—
—
—
—
8.1e-01
cases:3.47%
controls:2.01%
cases:2.70%
controls:0.46%
—
—
—
—
—
—
—
—
cases:4.15%
controls:1.88%
9
52
250
2538
7
12
252
2578
—
—
—
—
9
41
208
2141
Arthritis, unspecified
M13.9 [45567463]
1.3e+00
—
—
—
—
—
1.8e+00
cases:2.32%
controls:0.62%
—
—
—
—
—
—
—
—
—
—
cases:3.69%
controls:0.64%
6
16
253
2574
—
—
—
—
—
8
14
209
2168
tizanidine; oral
M03BX02 [21604116]
4.6e-01
5.4e-01
9.8e-01
1.0e+50
1.8e+00
7.3e-01
1.9e-01
cases:18.15%
controls:12.28%
cases:7.34%
controls:4.40%
cases:1.93%
controls:0.73%
cases:5.02%
controls:0.00%
cases:3.10%
controls:0.54%
cases:8.33%
controls:4.20%
cases:14.29%
controls:12.14%
47
318
212
2272
19
114
240
2476
5
19
254
2571
13
0
246
2590
8
14
250
2571
21
105
231
2395
31
265
186
1917
Functional capacity evaluation
443351003 [40481051]
—
—
—
—
—
1.8e+00
9.5e-01
—
—
—
—
—
—
—
—
—
—
cases:3.17%
controls:0.56%
cases:4.61%
controls:1.83%
—
—
—
—
—
8
14
244
2486
10
40
207
2142
Natriuretic peptide B [Mass/volume] in Serum or Plasma
30934-4 [3011960]
—
—
—
1.0e+50
—
—
1.8e+00
—
—
—
—
—
—
cases:1.93%
controls:0.00%
—
—
—
—
cases:4.61%
controls:0.82%
—
—
—
5
0
254
2590
—
—
10
18
207
2164
diclofenac; oral, parenteral, rectal
M01AB05 [21603945]
4.2e-01
4.9e-01
1.7e+00
—
—
5.2e-01
3.9e-01
cases:20.46%
controls:14.52%
cases:7.72%
controls:4.86%
cases:3.09%
controls:0.58%
—
—
—
—
cases:7.54%
controls:4.64%
cases:19.35%
controls:13.93%
53
376
206
2214
20
126
239
2464
8
15
251
2575
—
—
19
116
233
2384
42
304
175
1878
Uroflowmetry
44856007 [4261340]
—
1.2e+00
—
—
—
—
1.7e+00
—
—
cases:1.93%
controls:0.62%
—
—
—
—
—
—
—
—
cases:5.53%
controls:1.10%
—
5
16
254
2574
—
—
—
—
12
24
205
2158
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]
2.5e-01
5.6e-01
9.1e-01
—
1.1e+00
5.7e-01
5.1e-01
cases:27.41%
controls:22.78%
cases:23.17%
controls:14.63%
cases:3.86%
controls:1.58%
—
—
cases:4.26%
controls:1.39%
cases:24.21%
controls:15.36%
cases:44.70%
controls:32.68%
71
590
188
2000
60
379
199
2211
10
41
249
2549
—
11
36
247
2549
61
384
191
2116
97
713
120
1469
Borrelia burgdorferi IgG Ab [Units/volume] in Serum
7817-0 [3016888]
1.6e+00
—
—
—
—
—
1.1e+00
cases:3.86%
controls:0.77%
—
—
—
—
—
—
—
—
—
—
cases:3.23%
controls:1.10%
10
20
249
2570
—
—
—
—
—
7
24
210
2158
Borrelia burgdorferi IgM Ab [Units/volume] in Serum
7818-8 [3008230]
1.6e+00
—
—
—
—
—
1.1e+00
cases:3.86%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
cases:3.69%
controls:1.24%
10
21
249
2569
—
—
—
—
—
8
27
209
2155
codeine and paracetamol
N02AJ06 [1123647]
3.6e-01
7.7e-01
8.6e-01
—
1.3e+00
8.1e-01
5.5e-01
cases:18.53%
controls:13.67%
cases:10.42%
controls:5.10%
cases:2.70%
controls:1.16%
—
—
cases:3.49%
controls:1.01%
cases:10.32%
controls:4.88%
cases:19.82%
controls:12.51%
48
354
211
2236
27
132
232
2458
7
30
252
2560
—
9
26
249
2559
26
122
226
2378
43
273
174
1909
Bilirubin.conjugated [Moles/volume] in Serum or Plasma
29760-6 [3005772]
—
7.4e-01
—
—
—
1.4e+00
1.6e+00
—
—
cases:1.93%
controls:0.93%
—
—
—
—
—
—
cases:2.78%
controls:0.72%
cases:8.29%
controls:1.83%
—
5
24
254
2566
—
—
—
7
18
245
2482
18
40
199
2142
epinephrine; parenteral
C01CA24 [21600303]
1.6e+00
1.6e+00
—
—
—
—
1.2e+00
cases:4.25%
controls:0.93%
cases:1.93%
controls:0.39%
—
—
—
—
—
—
—
—
cases:2.76%
controls:0.82%
11
24
248
2566
5
10
254
2580
—
—
—
—
6
18
211
2164
epinephrine
S01EA01 [21603673]
1.6e+00
1.6e+00
—
—
—
—
1.2e+00
cases:4.25%
controls:0.93%
cases:1.93%
controls:0.39%
—
—
—
—
—
—
—
—
cases:2.76%
controls:0.82%
11
24
248
2566
5
10
254
2580
—
—
—
—
6
18
211
2164
Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma
48065-7 [3051714]
3.7e-01
1.5e+00
—
—
—
3.5e-01
8.5e-01
cases:5.02%
controls:3.51%
cases:4.25%
controls:0.97%
—
—
—
—
—
—
cases:1.98%
controls:1.40%
cases:9.22%
controls:4.17%
13
91
246
2499
11
25
248
2565
—
—
—
5
35
247
2465
20
91
197
2091
Other general examinations
Z00.8 [45581001]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.07%
controls:1.19%
—
—
—
—
—
—
11
26
206
2156
rabeprazole; oral
A02BC04 [21600099]
1.5e+00
—
—
—
—
—
—
cases:3.47%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
—
—
9
21
250
2569
—
—
—
—
—
—
dexrabeprazole
A02BC07 [45893509]
1.5e+00
—
—
—
—
—
—
cases:3.47%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
—
—
9
21
250
2569
—
—
—
—
—
—
Celiac disease serology panel - Serum
94494-2 [36660697]
1.1e+00
—
—
—
—
—
1.5e+00
cases:3.09%
controls:1.08%
—
—
—
—
—
—
—
—
—
—
cases:6.45%
controls:1.56%
8
28
251
2562
—
—
—
—
—
14
34
203
2148
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
1.1e-01
3.9e-01
3.1e-01
—
7.8e-01
8.7e-01
5.8e-01
cases:18.15%
controls:16.53%
cases:14.67%
controls:10.46%
cases:1.93%
controls:1.43%
—
—
cases:3.88%
controls:1.82%
cases:19.84%
controls:9.40%
cases:33.18%
controls:21.81%
47
428
212
2162
38
271
221
2319
5
37
254
2553
—
10
47
248
2538
50
235
202
2265
72
476
145
1706
Myalgia
M79.1 [45587062]
1.3e-01
1.7e+00
—
—
—
—
1.4e+00
cases:1.93%
controls:1.70%
cases:1.93%
controls:0.35%
—
—
—
—
—
—
—
—
cases:6.45%
controls:1.60%
5
44
254
2546
5
9
254
2581
—
—
—
—
14
35
203
2147
Nuclear Ab [Titer] in Serum
29953-7 [3037522]
-5.0e-02
5.5e-01
—
—
—
—
1.4e+00
cases:2.32%
controls:2.43%
cases:1.93%
controls:1.12%
—
—
—
—
—
—
—
—
cases:9.22%
controls:2.38%
6
63
253
2527
5
29
254
2561
—
—
—
—
20
52
197
2130
fluticasone; nasal
R01AD08 [21605050]
6.9e-01
2.2e-01
—
—
—
4.1e-01
7.3e-01
cases:14.29%
controls:7.72%
cases:4.25%
controls:3.44%
—
—
—
—
—
—
cases:5.56%
controls:3.76%
cases:16.13%
controls:8.48%
37
200
222
2390
11
89
248
2501
—
—
—
14
94
238
2406
35
185
182
1997
fluticasone furoate; nasal
R01AD12 [21605053]
6.9e-01
2.2e-01
—
—
—
4.1e-01
7.3e-01
cases:14.29%
controls:7.72%
cases:4.25%
controls:3.44%
—
—
—
—
—
—
cases:5.56%
controls:3.76%
cases:16.13%
controls:8.48%
37
200
222
2390
11
89
248
2501
—
—
—
14
94
238
2406
35
185
182
1997
salbutamol; inhalant
R03AC02 [21603256]
6.7e-01
4.0e-01
—
—
—
2.2e-01
7.3e-01
cases:23.94%
controls:13.82%
cases:9.27%
controls:6.41%
—
—
—
—
—
—
cases:8.33%
controls:6.80%
cases:25.81%
controls:14.34%
62
358
197
2232
24
166
235
2424
—
—
—
21
170
231
2330
56
313
161
1869
Carcinoembryonic Ag [Mass/volume] in Serum or Plasma
2039-6 [3003785]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.61%
controls:1.19%
—
—
—
—
—
—
10
26
207
2156
ketoprofen; ointment
M02AA10 [21604046]
1.4e+00
-1.0e+50
—
—
—
—
1.2e+00
cases:5.02%
controls:1.31%
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
cases:2.76%
controls:0.87%
13
34
246
2556
0
8
259
2582
—
—
—
—
6
19
211
2163
Urate [Moles/volume] in Serum or Plasma
14933-6 [3026493]
1.6e-01
4.5e-01
—
—
—
1.4e+00
7.3e-01
cases:5.02%
controls:4.32%
cases:2.70%
controls:1.74%
—
—
—
—
—
—
cases:6.35%
controls:1.68%
cases:10.14%
controls:5.13%
13
112
246
2478
7
45
252
2545
—
—
—
16
42
236
2458
22
112
195
2070
Intravenous general anesthesia
WX404 [2001310807]
6.2e-01
-1.0e+50
-1.0e+50
—
—
—
1.4e+00
cases:5.41%
controls:2.97%
cases:0.00%
controls:1.16%
cases:0.00%
controls:0.19%
—
—
—
—
—
—
cases:5.07%
controls:1.33%
14
77
245
2513
0
30
259
2560
0
5
259
2585
—
—
—
11
29
206
2153
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
1.4e+00
—
—
—
—
1.3e+00
8.8e-01
cases:5.41%
controls:1.43%
—
—
—
—
—
—
—
—
cases:1.98%
controls:0.56%
cases:4.61%
controls:1.97%
14
37
245
2553
—
—
—
—
5
14
247
2486
10
43
207
2139
hydrocortisone aceponate
D07AC16 [21602135]
6.2e-01
1.4e+00
—
—
—
4.8e-01
5.5e-01
cases:11.20%
controls:6.33%
cases:7.72%
controls:2.08%
—
—
—
—
—
—
cases:4.37%
controls:2.76%
cases:11.98%
controls:7.29%
29
164
230
2426
20
54
239
2536
—
—
—
11
69
241
2431
26
159
191
2023
hydrocortisone
C05AA01 [21601608]
6.0e-01
1.4e+00
—
—
—
4.8e-01
5.4e-01
cases:11.20%
controls:6.49%
cases:7.72%
controls:2.08%
—
—
—
—
—
—
cases:4.37%
controls:2.76%
cases:11.98%
controls:7.33%
29
168
230
2422
20
54
239
2536
—
—
—
11
69
241
2431
26
160
191
2022
hydrocortisone
D07AA02 [21602102]
6.2e-01
1.4e+00
—
—
—
4.8e-01
5.5e-01
cases:11.20%
controls:6.33%
cases:7.72%
controls:2.08%
—
—
—
—
—
—
cases:4.37%
controls:2.76%
cases:11.98%
controls:7.29%
29
164
230
2426
20
54
239
2536
—
—
—
11
69
241
2431
26
159
191
2023
hydrocortisone butyrate
D07AB02 [21602106]
6.2e-01
1.4e+00
—
—
—
4.8e-01
5.5e-01
cases:11.20%
controls:6.33%
cases:7.72%
controls:2.08%
—
—
—
—
—
—
cases:4.37%
controls:2.76%
cases:11.98%
controls:7.29%
29
164
230
2426
20
54
239
2536
—
—
—
11
69
241
2431
26
159
191
2023
hydrocortisone buteprate
D07AB11 [21602115]
6.2e-01
1.4e+00
—
—
—
4.8e-01
5.5e-01
cases:11.20%
controls:6.33%
cases:7.72%
controls:2.08%
—
—
—
—
—
—
cases:4.37%
controls:2.76%
cases:11.98%
controls:7.29%
29
164
230
2426
20
54
239
2536
—
—
—
11
69
241
2431
26
159
191
2023
hydrocortisone
A07EA02 [21600654]
6.0e-01
1.4e+00
—
—
—
4.8e-01
5.4e-01
cases:11.20%
controls:6.49%
cases:7.72%
controls:2.08%
—
—
—
—
—
—
cases:4.37%
controls:2.76%
cases:11.98%
controls:7.33%
29
168
230
2422
20
54
239
2536
—
—
—
11
69
241
2431
26
160
191
2022
Hand Surgery
40 [38004480]
6.8e-01
—
—
1.0e+50
—
1.4e+00
2.5e-01
cases:4.25%
controls:2.20%
—
—
—
—
cases:1.93%
controls:0.00%
—
—
cases:4.37%
controls:1.16%
cases:4.15%
controls:3.25%
11
57
248
2533
—
—
5
0
254
2590
—
11
29
241
2471
9
71
208
2111
Person consulting for explanation of investigation findings
Z71.2 [45552100]
5.2e-01
4.1e-01
—
—
—
1.3e+00
7.1e-01
cases:5.79%
controls:3.51%
cases:2.32%
controls:1.54%
—
—
—
—
—
—
cases:4.76%
controls:1.36%
cases:9.22%
controls:4.77%
15
91
244
2499
6
40
253
2550
—
—
—
12
34
240
2466
20
104
197
2078
Respiratory and circulatory monitoring
WX700 [2001310817]
4.6e-01
1.5e+00
—
—
—
1.4e+00
1.3e+00
cases:3.09%
controls:1.97%
cases:2.70%
controls:0.62%
—
—
—
—
—
—
cases:1.98%
controls:0.52%
cases:5.53%
controls:1.60%
8
51
251
2539
7
16
252
2574
—
—
—
5
13
247
2487
12
35
205
2147
Headache
R51.80 [2000503603]
9.5e-01
1.5e+00
—
—
—
—
1.3e+00
cases:4.63%
controls:1.85%
cases:2.32%
controls:0.54%
—
—
—
—
—
—
—
—
cases:5.53%
controls:1.60%
12
48
247
2542
6
14
253
2576
—
—
—
—
12
35
205
2147
codeine; oral
R05DA04 [21603399]
1.3e+00
—
—
—
—
—
1.6e-01
cases:6.95%
controls:2.08%
—
—
—
—
—
—
—
—
—
—
cases:3.23%
controls:2.75%
18
54
241
2536
—
—
—
—
—
7
60
210
2122
aciclovir; oral, parenteral
J05AB01 [21603131]
1.2e+00
—
—
—
—
9.2e-01
8.1e-01
cases:8.11%
controls:2.51%
—
—
—
—
—
—
—
—
cases:1.98%
controls:0.80%
cases:5.99%
controls:2.75%
21
65
238
2525
—
—
—
—
5
20
247
2480
13
60
204
2122
General anesthesia, balanced
WX408 [2001310808]
6.8e-01
6.2e-01
—
—
—
—
1.2e+00
cases:6.56%
controls:3.44%
cases:1.93%
controls:1.04%
—
—
—
—
—
—
—
—
cases:5.99%
controls:1.83%
17
89
242
2501
5
27
254
2563
—
—
—
—
13
40
204
2142
Acute bronchitis, unspecified
J20.9 [45562445]
8.1e-01
—
—
—
—
1.4e+00
1.2e+00
cases:4.63%
controls:2.12%
—
—
—
—
—
—
—
—
cases:1.98%
controls:0.48%
cases:7.37%
controls:2.29%
12
55
247
2535
—
—
—
—
5
12
247
2488
16
50
201
2132
Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection
6357-8 [3024950]
6.4e-01
7.4e-01
—
—
—
1.2e+00
1.2e+00
cases:4.25%
controls:2.28%
cases:1.93%
controls:0.93%
—
—
—
—
—
—
cases:2.78%
controls:0.84%
cases:8.76%
controls:2.75%
11
59
248
2531
5
24
254
2566
—
—
—
7
21
245
2479
19
60
198
2122
Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection
21416-3 [3003510]
5.6e-01
—
—
—
—
9.2e-01
1.2e+00
cases:3.47%
controls:2.01%
—
—
—
—
—
—
—
—
cases:1.98%
controls:0.80%
cases:7.83%
controls:2.52%
9
52
250
2538
—
—
—
—
5
20
247
2480
17
55
200
2127
hydrocortisone
S02BA01 [21605166]
3.8e-01
1.2e+00
—
—
—
3.6e-01
5.0e-01
cases:8.11%
controls:5.68%
cases:6.18%
controls:1.97%
—
—
—
—
—
—
cases:3.57%
controls:2.52%
cases:10.60%
controls:6.69%
21
147
238
2443
16
51
243
2539
—
—
—
9
63
243
2437
23
146
194
2036
Psychiatry
26 [38004469]
7.3e-01
9.5e-01
9.7e-01
—
1.3e+00
1.2e+00
7.5e-01
cases:10.04%
controls:5.10%
cases:5.79%
controls:2.32%
cases:2.32%
controls:0.89%
—
—
cases:3.10%
controls:0.85%
cases:6.75%
controls:2.16%
cases:8.76%
controls:4.35%
26
132
233
2458
15
60
244
2530
6
23
253
2567
—
8
22
250
2563
17
54
235
2446
19
95
198
2087
Cough
R05 [45606792]
4.1e-01
1.4e+00
—
—
—
1.3e+00
1.2e+00
cases:4.25%
controls:2.86%
cases:2.32%
controls:0.58%
—
—
—
—
—
—
cases:2.78%
controls:0.76%
cases:6.91%
controls:2.25%
11
74
248
2516
6
15
253
2575
—
—
—
7
19
245
2481
15
49
202
2133
Coloscopy
UJF32 [2001305029]
7.9e-01
9.3e-01
—
—
-1.0e+50
—
1.2e+00
cases:7.34%
controls:3.47%
cases:2.32%
controls:0.93%
—
—
—
—
cases:0.00%
controls:0.19%
—
—
cases:10.14%
controls:3.44%
19
90
240
2500
6
24
253
2566
—
—
0
5
258
2580
—
22
75
195
2107
oxazepam; oral
N05BA04 [21604569]
6.2e-01
8.6e-01
-1.0e+50
—
—
1.1e+00
3.5e-01
cases:8.11%
controls:4.52%
cases:4.63%
controls:2.01%
cases:0.00%
controls:0.39%
—
—
—
—
cases:5.16%
controls:1.72%
cases:6.91%
controls:5.00%
21
117
238
2473
12
52
247
2538
0
10
259
2580
—
—
13
43
239
2457
15
109
202
2073
Other specified counselling
Z71.8 [45581061]
5.7e-01
3.7e-01
—
—
—
1.1e+00
5.7e-01
cases:6.56%
controls:3.82%
cases:3.09%
controls:2.16%
—
—
—
—
—
—
cases:6.75%
controls:2.28%
cases:11.52%
controls:6.87%
17
99
242
2491
8
56
251
2534
—
—
—
17
57
235
2443
25
150
192
2032
One hour or less
ZXE00 [2001311394]
6.6e-01
4.5e-01
—
—
—
1.3e+00
1.1e+00
cases:9.65%
controls:5.21%
cases:3.47%
controls:2.24%
—
—
—
—
—
—
cases:3.57%
controls:1.00%
cases:9.22%
controls:3.25%
25
135
234
2455
9
58
250
2532
—
—
—
9
25
243
2475
20
71
197
2111
Transferrin.carbohydrate deficient.disialo/Transferrin.total in Serum or Plasma
21573-1 [3003031]
3.2e-01
—
—
—
—
—
1.1e+00
cases:2.32%
controls:1.70%
—
—
—
—
—
—
—
—
—
—
cases:6.45%
controls:2.25%
6
44
253
2546
—
—
—
—
—
14
49
203
2133
Sedation and analgesia
WX002 [2001310758]
1.1e+00
—
—
—
—
1.4e+00
1.2e+00
cases:5.02%
controls:1.74%
—
—
—
—
—
—
—
—
cases:1.98%
controls:0.48%
cases:5.07%
controls:1.65%
13
45
246
2545
—
—
—
—
5
12
247
2488
11
36
206
2146
antibiotics in combination with other drugs
S01AA20 [21603571]
4.2e-01
1.1e+00
—
—
—
2.0e-01
3.6e-01
cases:10.04%
controls:6.83%
cases:5.79%
controls:2.05%
—
—
—
—
—
—
cases:2.78%
controls:2.28%
cases:10.60%
controls:7.65%
26
177
233
2413
15
53
244
2537
—
—
—
7
57
245
2443
23
167
194
2015
pregabalin; oral
N02BF02 [955152]
1.1e+00
6.4e-01
—
—
—
7.5e-01
9.1e-01
cases:9.27%
controls:3.36%
cases:3.09%
controls:1.66%
—
—
—
—
—
—
cases:3.57%
controls:1.72%
cases:8.29%
controls:3.53%
24
87
235
2503
8
43
251
2547
—
—
—
9
43
243
2457
18
77
199
2105
azithromycin; oral, parenteral
J01FA10 [21602978]
2.9e-01
1.1e+00
—
—
-1.0e+50
1.0e+00
4.7e-01
cases:13.51%
controls:10.42%
cases:6.18%
controls:2.20%
—
—
—
—
cases:0.00%
controls:0.19%
cases:5.95%
controls:2.28%
cases:10.60%
controls:6.92%
35
270
224
2320
16
57
243
2533
—
—
0
5
258
2580
15
57
237
2443
23
151
194
2031
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
5.7e-01
8.5e-01
—
—
—
5.1e-01
1.0e+00
cases:10.81%
controls:6.41%
cases:5.79%
controls:2.55%
—
—
—
—
—
—
cases:4.37%
controls:2.68%
cases:16.59%
controls:6.51%
28
166
231
2424
15
66
244
2524
—
—
—
11
67
241
2433
36
142
181
2040
Malaise and fatigue
R53 [45553741]
1.8e-01
1.2e+00
—
—
—
6.6e-01
1.0e+00
cases:3.09%
controls:2.59%
cases:3.09%
controls:0.97%
—
—
—
—
—
—
cases:2.38%
controls:1.24%
cases:9.68%
controls:3.62%
8
67
251
2523
8
25
251
2565
—
—
—
6
31
246
2469
21
79
196
2103
Short blood count panel - Blood
55429-5 [40758558]
5.2e-01
4.9e-01
—
—
—
1.0e+00
6.5e-01
cases:7.72%
controls:4.75%
cases:4.63%
controls:2.90%
—
—
—
—
—
—
cases:6.75%
controls:2.48%
cases:11.06%
controls:6.10%
20
123
239
2467
12
75
247
2515
—
—
—
17
62
235
2438
24
133
193
2049
Transvaginal ultrasound examination of uterus, parametria and lower abdomen
LC2BE [2001306544]
5.4e-01
1.0e+00
—
—
-1.0e+50
1.0e+00
1.0e+00
cases:6.95%
controls:4.17%
cases:2.70%
controls:1.00%
—
—
—
—
cases:0.00%
controls:0.31%
cases:2.38%
controls:0.88%
cases:9.68%
controls:3.67%
18
108
241
2482
7
26
252
2564
—
—
0
8
258
2577
6
22
246
2478
21
80
196
2102
ketoprofen; oral, parenteral, rectal
M01AE03 [21603969]
1.0e+00
—
—
—
—
—
6.4e-01
cases:10.42%
controls:3.98%
—
—
—
—
—
—
—
—
—
—
cases:5.07%
controls:2.75%
27
103
232
2487
—
—
—
—
—
11
60
206
2122
piroxicam; ointment
M02AA07 [21604043]
1.0e+00
—
—
—
—
—
1.8e-01
cases:8.11%
controls:3.09%
—
—
—
—
—
—
—
—
—
—
cases:3.23%
controls:2.70%
21
80
238
2510
—
—
—
—
—
7
59
210
2123
piroxicam; oral, parenteral, rectal
M01AC01 [21603961]
1.0e+00
4.9e-01
—
—
—
—
3.8e-01
cases:9.27%
controls:3.59%
cases:1.93%
controls:1.20%
—
—
—
—
—
—
—
—
cases:4.15%
controls:2.89%
24
93
235
2497
5
31
254
2559
—
—
—
—
9
63
208
2119
combinations of corticosteroids
D07XB30 [21602188]
4.7e-01
9.9e-01
—
—
—
7.5e-01
6.2e-01
cases:14.67%
controls:9.73%
cases:8.11%
controls:3.17%
—
—
—
—
—
—
cases:7.94%
controls:3.92%
cases:18.89%
controls:11.09%
38
252
221
2338
21
82
238
2508
—
—
—
20
98
232
2402
41
242
176
1940
combinations of corticosteroids
D07AB30 [21602118]
4.7e-01
9.9e-01
—
—
—
7.5e-01
6.2e-01
cases:14.67%
controls:9.73%
cases:8.11%
controls:3.17%
—
—
—
—
—
—
cases:7.94%
controls:3.92%
cases:18.89%
controls:11.09%
38
252
221
2338
21
82
238
2508
—
—
—
20
98
232
2402
41
242
176
1940
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
-3.8e-01
1.4e-01
-1.0e+50
—
-1.0e+50
8.4e-01
9.8e-01
cases:3.09%
controls:4.44%
cases:2.70%
controls:2.36%
cases:0.00%
controls:0.31%
—
—
cases:0.00%
controls:0.31%
cases:3.97%
controls:1.76%
cases:11.06%
controls:4.45%
8
115
251
2475
7
61
252
2529
0
8
259
2582
—
0
8
258
2577
10
44
242
2456
24
97
193
2085
Epithelial cells.squamous [#/volume] in Urine by Automated count
51486-9 [3029879]
6.9e-01
1.1e+00
—
—
—
6.7e-01
9.8e-01
cases:3.86%
controls:1.97%
cases:2.70%
controls:0.89%
—
—
—
—
—
—
cases:2.78%
controls:1.44%
cases:9.22%
controls:3.67%
10
51
249
2539
7
23
252
2567
—
—
—
7
36
245
2464
20
80
197
2102
Osmolality of Urine
2695-5 [3026782]
7.1e-02
7.1e-01
—
—
—
1.2e+00
9.6e-01
cases:3.47%
controls:3.24%
cases:3.09%
controls:1.54%
—
—
—
—
—
—
cases:3.97%
controls:1.24%
cases:10.14%
controls:4.12%
9
84
250
2506
8
40
251
2550
—
—
—
10
31
242
2469
22
90
195
2092
Bacteria [Presence] in Urine
87829-8 [36304419]
5.4e-01
1.1e+00
—
—
-1.0e+50
9.8e-01
9.5e-01
cases:6.18%
controls:3.71%
cases:4.63%
controls:1.66%
—
—
—
—
cases:0.00%
controls:0.35%
cases:4.76%
controls:1.84%
cases:14.29%
controls:6.05%
16
96
243
2494
12
43
247
2547
—
—
0
9
258
2576
12
46
240
2454
31
132
186
2050
Pain localized to other parts of lower abdomen
R10.3 [45534426]
9.5e-01
1.3e+00
—
—
—
1.1e+00
8.4e-01
cases:7.34%
controls:2.97%
cases:3.47%
controls:1.00%
—
—
—
—
—
—
cases:3.57%
controls:1.16%
cases:8.76%
controls:3.99%
19
77
240
2513
9
26
250
2564
—
—
—
9
29
243
2471
19
87
198
2095
Chest pain, unspecified
R07.4 [45558450]
2.3e-01
7.0e-01
—
—
—
1.2e+00
9.1e-01
cases:5.02%
controls:4.02%
cases:1.93%
controls:0.97%
—
—
—
—
—
—
cases:2.78%
controls:0.88%
cases:8.76%
controls:3.71%
13
104
246
2486
5
25
254
2565
—
—
—
7
22
245
2478
19
81
198
2101
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
2.4e-01
3.6e-01
—
—
-1.0e+50
1.2e+00
9.0e-01
cases:3.86%
controls:3.05%
cases:2.32%
controls:1.62%
—
—
—
—
cases:0.00%
controls:0.27%
cases:3.97%
controls:1.24%
cases:10.60%
controls:4.58%
10
79
249
2511
6
42
253
2548
—
—
0
7
258
2578
10
31
242
2469
23
100
194
2082
Low back pain
M54.5 [45553207]
5.1e-01
1.5e-01
—
—
—
9.6e-01
9.0e-01
cases:8.88%
controls:5.52%
cases:2.32%
controls:2.01%
—
—
—
—
—
—
cases:5.16%
controls:2.04%
cases:13.36%
controls:5.91%
23
143
236
2447
6
52
253
2538
—
—
—
13
51
239
2449
29
129
188
2053
Tissue transglutaminase IgA Ab [Units/volume] in Serum
31017-7 [3019050]
7.9e-01
2.3e-01
—
—
—
—
8.9e-01
cases:6.95%
controls:3.28%
cases:2.70%
controls:2.16%
—
—
—
—
—
—
—
—
cases:12.90%
controls:5.73%
18
85
241
2505
7
56
252
2534
—
—
—
—
28
125
189
2057
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
-1.3e-01
7.8e-01
—
—
—
3.9e-01
8.8e-01
cases:6.56%
controls:7.37%
cases:8.49%
controls:4.09%
—
—
—
—
—
—
cases:5.95%
controls:4.12%
cases:19.82%
controls:9.26%
17
191
242
2399
22
106
237
2484
—
—
—
15
103
237
2397
43
202
174
1980
Epithelial cells.non-squamous [#/volume] in Urine by Automated count
51485-1 [3030306]
7.8e-01
9.7e-01
—
—
-1.0e+50
7.5e-01
8.8e-01
cases:3.86%
controls:1.81%
cases:2.32%
controls:0.89%
—
—
—
—
cases:0.00%
controls:0.27%
cases:3.17%
controls:1.52%
cases:9.22%
controls:4.03%
10
47
249
2543
6
23
253
2567
—
—
0
7
258
2578
8
38
244
2462
20
88
197
2094
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
-3.4e-02
6.1e-01
—
—
1.1e+00
6.6e-01
8.6e-01
cases:8.49%
controls:8.76%
cases:7.34%
controls:4.13%
—
—
—
—
cases:2.33%
controls:0.81%
cases:8.33%
controls:4.48%
cases:23.96%
controls:11.78%
22
227
237
2363
19
107
240
2483
—
—
6
21
252
2564
21
112
231
2388
52
257
165
1925
Outpatient Hospital
22 [8756]
2.3e-01
8.6e-01
1.3e+00
1.0e+50
1.5e+00
6.7e-01
5.3e-01
cases:25.48%
controls:21.31%
cases:13.13%
controls:6.02%
cases:2.70%
controls:0.73%
cases:3.47%
controls:0.00%
cases:2.71%
controls:0.62%
cases:9.92%
controls:5.32%
cases:23.50%
controls:15.26%
66
552
193
2038
34
156
225
2434
7
19
252
2571
9
0
250
2590
7
16
251
2569
25
133
227
2367
51
333
166
1849
Implementation of physical therapy rehabilitation plan
SPAT1223 [2001700324]
0.0e+00
5.2e-01
—
—
—
—
8.6e-01
cases:4.63%
controls:4.63%
cases:2.32%
controls:1.39%
—
—
—
—
—
—
—
—
cases:9.68%
controls:4.35%
12
120
247
2470
6
36
253
2554
—
—
—
—
21
95
196
2087
esomeprazole; oral, parenteral
A02BC05 [21600100]
4.8e-01
7.1e-01
—
—
—
6.1e-01
8.5e-01
cases:11.20%
controls:7.26%
cases:7.34%
controls:3.75%
—
—
—
—
—
—
cases:6.35%
controls:3.56%
cases:15.21%
controls:7.15%
29
188
230
2402
19
97
240
2493
—
—
—
16
89
236
2411
33
156
184
2026
Upper gastrointestinal surgery
106 [44777669]
1.8e-02
-3.0e-01
-1.0e+50
—
—
6.4e-01
8.3e-01
cases:6.95%
controls:6.83%
cases:2.32%
controls:3.09%
cases:0.00%
controls:0.54%
—
—
—
—
cases:5.56%
controls:3.00%
cases:15.67%
controls:7.47%
18
177
241
2413
6
80
253
2510
0
14
259
2576
—
—
14
75
238
2425
34
163
183
2019
Tissue Pathology biopsy report
66121-5 [40768804]
4.3e-01
4.6e-01
—
—
—
4.5e-01
8.2e-01
cases:9.65%
controls:6.49%
cases:3.86%
controls:2.47%
—
—
—
—
—
—
cases:3.17%
controls:2.04%
cases:16.13%
controls:7.79%
25
168
234
2422
10
64
249
2526
—
—
—
8
51
244
2449
35
170
182
2012
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
3.9e-01
9.0e-01
—
—
-1.0e+50
7.8e-01
8.0e-01
cases:5.79%
controls:3.98%
cases:4.63%
controls:1.93%
—
—
—
—
cases:0.00%
controls:0.39%
cases:4.76%
controls:2.24%
cases:13.36%
controls:6.46%
15
103
244
2487
12
50
247
2540
—
—
0
10
258
2575
12
56
240
2444
29
141
188
2041
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
1.4e-01
7.8e-01
—
—
—
7.8e-01
8.0e-01
cases:8.88%
controls:7.84%
cases:8.88%
controls:4.29%
—
—
—
—
—
—
cases:7.94%
controls:3.80%
cases:19.35%
controls:9.76%
23
203
236
2387
23
111
236
2479
—
—
—
20
95
232
2405
42
213
175
1969
Thorax X-ray examination
GD1AA [2001303617]
3.6e-01
7.5e-01
—
—
—
8.0e-01
7.7e-01
cases:9.65%
controls:6.91%
cases:5.79%
controls:2.82%
—
—
—
—
—
—
cases:4.76%
controls:2.20%
cases:13.82%
controls:6.92%
25
179
234
2411
15
73
244
2517
—
—
—
12
55
240
2445
30
151
187
2031
Basophils/Leukocytes in Blood
30180-4 [3022096]
1.5e-01
6.4e-01
—
—
—
6.0e-01
7.6e-01
cases:10.81%
controls:9.46%
cases:9.27%
controls:5.10%
—
—
—
—
—
—
cases:8.73%
controls:5.00%
cases:21.66%
controls:11.41%
28
245
231
2345
24
132
235
2458
—
—
—
22
125
230
2375
47
249
170
1933
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
1.4e-01
6.4e-01
—
—
—
6.0e-01
7.6e-01
cases:10.81%
controls:9.50%
cases:9.27%
controls:5.10%
—
—
—
—
—
—
cases:8.73%
controls:5.00%
cases:21.66%
controls:11.46%
28
246
231
2344
24
132
235
2458
—
—
—
22
125
230
2375
47
250
170
1932
Telehealth
OMOP5556618 [722455]
2.2e-02
2.0e-01
7.6e-01
—
4.7e-01
7.4e-01
4.3e-01
cases:22.39%
controls:22.01%
cases:11.20%
controls:9.34%
cases:3.09%
controls:1.47%
—
—
cases:2.33%
controls:1.47%
cases:15.48%
controls:8.00%
cases:27.65%
controls:19.98%
58
570
201
2020
29
242
230
2348
8
38
251
2552
—
6
38
252
2547
39
200
213
2300
60
436
157
1746
Bacteria identified in Urine by Culture
630-4 [3026008]
4.3e-01
4.6e-01
—
—
-1.0e+50
7.3e-01
7.4e-01
cases:7.34%
controls:4.90%
cases:3.09%
controls:1.97%
—
—
—
—
cases:0.00%
controls:0.31%
cases:5.16%
controls:2.56%
cases:13.36%
controls:6.83%
19
127
240
2463
8
51
251
2539
—
—
0
8
258
2577
13
64
239
2436
29
149
188
2033
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
1.2e-01
6.3e-01
—
—
—
5.3e-01
7.4e-01
cases:13.90%
controls:12.55%
cases:8.88%
controls:4.94%
—
—
—
—
—
—
cases:9.13%
controls:5.56%
cases:31.34%
controls:17.87%
36
325
223
2265
23
128
236
2462
—
—
—
23
139
229
2361
68
390
149
1792
pH of Serum or Plasma
2753-2 [3018418]
4.0e-01
7.5e-01
—
—
—
7.9e-01
7.4e-01
cases:7.34%
controls:5.06%
cases:5.79%
controls:2.82%
—
—
—
—
—
—
cases:5.56%
controls:2.60%
cases:13.36%
controls:6.87%
19
131
240
2459
15
73
244
2517
—
—
—
14
65
238
2435
29
150
188
2032
Monocytes/Leukocytes in Blood
26485-3 [3019069]
1.3e-01
6.3e-01
—
—
—
6.5e-01
7.3e-01
cases:10.81%
controls:9.61%
cases:9.27%
controls:5.14%
—
—
—
—
—
—
cases:9.13%
controls:5.00%
cases:21.20%
controls:11.46%
28
249
231
2341
24
133
235
2457
—
—
—
23
125
229
2375
46
250
171
1932
Acute upper respiratory infection, unspecified
J06.9 [45562437]
7.3e-01
6.4e-01
—
—
—
5.8e-01
4.2e-01
cases:14.67%
controls:7.68%
cases:6.18%
controls:3.36%
—
—
—
—
—
—
cases:6.35%
controls:3.64%
cases:15.21%
controls:10.49%
38
199
221
2391
16
87
243
2503
—
—
—
16
91
236
2409
33
229
184
1953
Laceration/cut
S18 [2002000983]
3.0e-01
6.6e-01
—
—
—
9.4e-01
7.2e-01
cases:8.88%
controls:6.72%
cases:4.25%
controls:2.24%
—
—
—
—
—
—
cases:5.56%
controls:2.24%
cases:15.21%
controls:8.02%
23
174
236
2416
11
58
248
2532
—
—
—
14
56
238
2444
33
175
184
2007
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
1.7e-01
6.2e-01
—
—
1.2e+00
6.3e-01
7.1e-01
cases:10.04%
controls:8.61%
cases:8.49%
controls:4.75%
—
—
—
—
cases:1.94%
controls:0.58%
cases:8.33%
controls:4.60%
cases:21.66%
controls:11.92%
26
223
233
2367
22
123
237
2467
—
—
5
15
253
2570
21
115
231
2385
47
260
170
1922
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
1.3e-01
6.3e-01
—
—
—
5.5e-01
7.1e-01
cases:10.81%
controls:9.61%
cases:9.27%
controls:5.14%
—
—
—
—
—
—
cases:8.33%
controls:5.00%
cases:21.20%
controls:11.64%
28
249
231
2341
24
133
235
2457
—
—
—
21
125
231
2375
46
254
171
1928
Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 [3008486]
3.1e-01
6.9e-01
1.0e+00
—
1.3e+00
5.2e-01
4.5e-01
cases:22.78%
controls:17.80%
cases:17.76%
controls:9.77%
cases:2.70%
controls:0.97%
—
—
cases:3.49%
controls:0.93%
cases:17.06%
controls:10.88%
cases:33.64%
controls:24.43%
59
461
200
2129
46
253
213
2337
7
25
252
2565
—
9
24
249
2561
43
272
209
2228
73
533
144
1649
chloramphenicol
S01AA01 [21603554]
1.6e-01
6.7e-02
—
—
-1.0e+50
7.2e-01
6.8e-01
cases:9.65%
controls:8.34%
cases:3.09%
controls:2.90%
—
—
—
—
cases:0.00%
controls:0.54%
cases:5.95%
controls:3.00%
cases:16.59%
controls:9.12%
25
216
234
2374
8
75
251
2515
—
—
0
14
258
2571
15
75
237
2425
36
199
181
1983
chloramphenicol
S03AA08 [21605197]
1.6e-01
6.7e-02
—
—
-1.0e+50
7.2e-01
6.8e-01
cases:9.65%
controls:8.34%
cases:3.09%
controls:2.90%
—
—
—
—
cases:0.00%
controls:0.54%
cases:5.95%
controls:3.00%
cases:16.59%
controls:9.12%
25
216
234
2374
8
75
251
2515
—
—
0
14
258
2571
15
75
237
2425
36
199
181
1983
Eosinophils [#/volume] in Blood
26449-9 [3013115]
6.4e-02
7.0e-01
—
—
3.4e-01
4.9e-01
6.7e-01
cases:11.20%
controls:10.58%
cases:10.42%
controls:5.44%
—
—
—
—
cases:1.94%
controls:1.39%
cases:9.13%
controls:5.80%
cases:22.12%
controls:12.74%
29
274
230
2316
27
141
232
2449
—
—
5
36
253
2549
23
145
229
2355
48
278
169
1904
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
1.4e-01
6.0e-01
—
—
4.2e-01
6.4e-01
6.5e-01
cases:11.20%
controls:9.85%
cases:9.27%
controls:5.33%
—
—
—
—
cases:1.94%
controls:1.28%
cases:9.52%
controls:5.24%
cases:20.74%
controls:12.01%
29
255
230
2335
24
138
235
2452
—
—
5
33
253
2552
24
131
228
2369
45
262
172
1920
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
1.2e-01
6.0e-01
—
—
1.9e-01
4.8e-01
6.5e-01
cases:13.13%
controls:11.78%
cases:11.97%
controls:6.95%
—
—
—
—
cases:2.33%
controls:1.93%
cases:10.71%
controls:6.92%
cases:24.88%
controls:14.76%
34
305
225
2285
31
180
228
2410
—
—
6
50
252
2535
27
173
225
2327
54
322
163
1860
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
5.3e-01
1.7e-01
—
—
1.8e+00
5.5e-01
6.5e-01
cases:11.58%
controls:7.14%
cases:5.79%
controls:4.94%
—
—
—
—
cases:2.33%
controls:0.39%
cases:8.33%
controls:5.00%
cases:19.82%
controls:11.46%
30
185
229
2405
15
128
244
2462
—
—
6
10
252
2575
21
125
231
2375
43
250
174
1932
Essential (primary) hypertension
I10 [45591453]
2.1e-01
2.1e-01
—
—
9.3e-01
2.4e-01
6.5e-01
cases:16.22%
controls:13.59%
cases:8.88%
controls:7.30%
—
—
—
—
cases:2.71%
controls:1.08%
cases:9.52%
controls:7.64%
cases:27.65%
controls:16.68%
42
352
217
2238
23
189
236
2401
—
—
7
28
251
2557
24
191
228
2309
60
364
157
1818
cefalexin; oral
J01DB01 [21602870]
4.4e-01
5.1e-01
—
—
—
4.7e-01
6.4e-01
cases:37.07%
controls:27.45%
cases:13.51%
controls:8.61%
—
—
—
—
—
—
cases:13.89%
controls:9.12%
cases:39.17%
controls:25.44%
96
711
163
1879
35
223
224
2367
—
—
—
35
228
217
2272
85
555
132
1627
12 lead EKG panel
34534-8 [3044889]
2.4e-01
5.2e-01
—
—
—
4.3e-01
6.3e-01
cases:18.15%
controls:14.79%
cases:12.74%
controls:7.95%
—
—
—
—
—
—
cases:10.71%
controls:7.24%
cases:31.34%
controls:19.62%
47
383
212
2207
33
206
226
2384
—
—
—
27
181
225
2319
68
428
149
1754
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
3.9e-01
6.2e-01
7.0e-01
—
6.1e-01
4.4e-01
3.6e-01
cases:42.86%
controls:33.63%
cases:25.10%
controls:15.29%
cases:4.63%
controls:2.36%
—
—
cases:3.49%
controls:1.93%
cases:21.03%
controls:14.64%
cases:44.70%
controls:36.07%
111
871
148
1719
65
396
194
2194
12
61
247
2529
—
9
50
249
2535
53
366
199
2134
97
787
120
1395
ibuprofen
R02AX02 [1588667]
3.9e-01
6.2e-01
7.0e-01
—
6.1e-01
4.4e-01
3.6e-01
cases:42.86%
controls:33.63%
cases:25.10%
controls:15.29%
cases:4.63%
controls:2.36%
—
—
cases:3.49%
controls:1.93%
cases:21.03%
controls:14.64%
cases:44.70%
controls:36.07%
111
871
148
1719
65
396
194
2194
12
61
247
2529
—
9
50
249
2535
53
366
199
2134
97
787
120
1395
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
4.0e-01
1.7e-01
6.2e-01
—
8.0e-01
5.1e-01
6.1e-01
cases:40.15%
controls:31.08%
cases:19.31%
controls:16.80%
cases:5.41%
controls:2.97%
—
—
cases:5.81%
controls:2.71%
cases:24.21%
controls:16.08%
cases:49.77%
controls:34.97%
104
805
155
1785
50
435
209
2155
14
77
245
2513
—
15
70
243
2515
61
402
191
2098
108
763
109
1419
Infiltration anesthesia
WX110 [2001310767]
2.2e-01
3.5e-02
—
—
—
2.5e-01
5.7e-01
cases:22.01%
controls:18.46%
cases:7.34%
controls:7.10%
—
—
—
—
—
—
cases:8.33%
controls:6.64%
cases:31.80%
controls:20.94%
57
478
202
2112
19
184
240
2406
—
—
—
21
166
231
2334
69
457
148
1725
doxycycline; oral, parenteral
J01AA02 [21602800]
5.5e-01
4.1e-01
-1.0e+50
—
—
6.6e-01
5.6e-01
cases:24.71%
controls:15.98%
cases:6.18%
controls:4.17%
cases:0.00%
controls:0.35%
—
—
—
—
cases:7.54%
controls:4.04%
cases:22.12%
controls:13.98%
64
414
195
2176
16
108
243
2482
0
9
259
2581
—
—
19
101
233
2399
48
305
169
1877
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
1.7e-01
3.4e-01
4.6e-01
—
3.9e-01
4.8e-01
4.3e-01
cases:32.43%
controls:28.88%
cases:27.80%
controls:21.47%
cases:4.63%
controls:2.97%
—
—
cases:5.81%
controls:4.02%
cases:32.14%
controls:22.68%
cases:51.61%
controls:41.02%
84
748
175
1842
72
556
187
2034
12
77
247
2513
—
15
104
243
2481
81
567
171
1933
112
895
105
1287
Dedicated profession-specific psychiatric intervention, group
IER02 [2001304206]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
259
2585
—
—
—
—
—
—
Rehabilitation Hospital
283X00000X [38004285]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
0
7
217
2175
Risk factor cardiovascular disease
K22 [2002000551]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
0
7
259
2583
—
—
—
0
5
252
2495
—
SMOKING - SMOKE2: no - SMOKE3: never - SMOKE5: Unspecified
SMOKING-2-3-0 [2002330113]
1.5e-01
—
-1.0e+50
—
—
1.0e+50
1.0e+50
cases:6.56%
controls:5.68%
—
—
cases:0.00%
controls:0.19%
—
—
—
—
cases:1.98%
controls:0.00%
cases:5.07%
controls:0.00%
17
147
242
2443
—
0
5
259
2585
—
—
5
0
247
2500
11
0
206
2182
Benign neoplasm: Colon, unspecified
D12.6 [45576377]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
0
6
259
2584
—
—
—
—
—
finasteride; oral
G04CB01 [21602675]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
0
6
259
2584
—
0
6
258
2579
—
—
bisoprolol; oral
C07AB07 [21601689]
2.0e-01
8.7e-02
4.1e-01
-1.0e+50
-3.2e-02
3.4e-01
3.9e-01
cases:15.44%
controls:12.97%
cases:11.97%
controls:11.08%
cases:5.02%
controls:3.40%
cases:0.00%
controls:0.19%
cases:3.49%
controls:3.60%
cases:15.48%
controls:11.52%
cases:20.28%
controls:14.67%
40
336
219
2254
31
287
228
2303
13
88
246
2502
0
5
259
2585
9
93
249
2492
39
288
213
2212
44
320
173
1862
Influenza virus B RNA [Presence] in Nasopharynx by NAA with probe detection
76080-1 [46235759]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.50%
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
0
13
259
2577
0
7
259
2583
—
—
—
—
0
11
217
2171
sodium fluoride; oral
A01AA01 [21600005]
8.8e-01
-1.0e+50
-1.0e+50
—
—
—
6.0e-01
cases:1.93%
controls:0.81%
cases:0.00%
controls:0.62%
cases:0.00%
controls:0.19%
—
—
—
—
—
—
cases:2.30%
controls:1.28%
5
21
254
2569
0
16
259
2574
0
5
259
2585
—
—
—
5
28
212
2154
Choriogonadotropin.intact+Beta subunit [Mass/volume] in Serum or Plasma
93769-8 [1002102]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
0
9
217
2173
Kappa light chains.free [Mass/volume] in Serum
36916-5 [3034860]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
0
6
252
2494
—
Urine symptom/complaint other
U07 [2002001142]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.23%
controls:1.10%
—
—
—
—
—
—
7
24
210
2158
Dermatitis/atopic eczema
S87 [2002001051]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
259
2580
—
—
—
—
—
—
Ankle and foot CT
NH1AD [2001308236]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
0
5
259
2585
—
—
—
—
—
0
5
217
2177
Risk factor NOS
A23 [2002000158]
—
—
—
—
—
—
3.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.30%
controls:1.70%
—
—
—
—
—
—
5
37
212
2145
Observation for other suspected cardiovascular diseases
Z03.5 [45590692]
1.3e+00
—
—
—
—
—
1.4e+00
cases:1.93%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
cases:2.30%
controls:0.60%
5
14
254
2576
—
—
—
—
—
5
13
212
2169
Periodic check-up in occupational healthcare
SPAT1368 [2001700469]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
0
5
217
2177
Muscle strain
M62.6 [45587017]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
259
2584
—
—
—
—
—
—
Mycobacterium sp identified in Sputum by Organism specific culture
539-7 [3027544]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
0
5
217
2177
Animal/human bite
S13 [2002000978]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
8
217
2174
Enthesopathy, unspecified
M77.9 [45591933]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
259
2584
—
—
—
—
—
—
Urinary tract infection, site not specified
N39.0 [45548665]
-4.0e-02
—
—
—
—
—
4.9e-01
cases:1.93%
controls:2.01%
—
—
—
—
—
—
—
—
—
—
cases:3.69%
controls:2.29%
5
52
254
2538
—
—
—
—
—
8
50
209
2132
Viral intestinal infection, unspecified
A08.4 [45576230]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
0
9
217
2173
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]
4.0e-01
6.4e-01
—
—
1.7e+00
7.2e-01
4.6e-01
cases:10.42%
controls:7.22%
cases:6.18%
controls:3.36%
—
—
—
—
cases:1.94%
controls:0.35%
cases:6.35%
controls:3.20%
cases:15.21%
controls:10.17%
27
187
232
2403
16
87
243
2503
—
—
5
9
253
2576
16
80
236
2420
33
222
184
1960
glimepiride; oral
A10BB12 [21600761]
-1.0e+50
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.93%
—
—
—
—
—
—
cases:0.00%
controls:0.19%
—
—
—
—
0
24
259
2566
—
—
—
0
5
258
2580
—
—
Production of copy from X-ray picture
XX9AW [2001311036]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
6
217
2176
Other chronic obstructive pulmonary disease
J44 [45543268]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
259
2584
—
—
—
—
—
—
Examination and observation for unspecified reason
Z04.9 [45605102]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
6
217
2176
Erosion of teeth
K03.2 [45572183]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
0
8
259
2582
—
—
—
—
—
0
7
217
2175
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]
-2.6e-01
1.4e-01
—
—
-1.0e+50
2.0e-01
3.3e-01
cases:4.63%
controls:5.95%
cases:2.70%
controls:2.36%
—
—
—
—
cases:0.00%
controls:0.31%
cases:2.78%
controls:2.28%
cases:11.98%
controls:8.94%
12
154
247
2436
7
61
252
2529
—
—
0
8
258
2577
7
57
245
2443
26
195
191
1987
levetiracetam; oral, parenteral
N03AX14 [21604436]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
0
6
252
2494
—
Ultrasound examination of ovarian cyst
LA2AE [2001306398]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
259
2585
—
—
—
—
—
—
Implementation of occupational therapy rehabilitation plan
SPAT1226 [2001700327]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
259
2585
—
—
—
—
—
—
Radical radiotherapy
WF002 [2001310701]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
259
2585
—
—
—
—
—
—
Calculus of ureter
N20.1 [45582395]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
259
2584
—
—
—
—
—
—
valsartan and diuretics
C09DA03 [21601836]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
0
6
258
2579
—
—
Other primary gonarthrosis
M17.1 [45596493]
-9.8e-02
—
-1.0e+50
—
—
—
2.9e-01
cases:2.70%
controls:2.97%
—
—
cases:0.00%
controls:0.19%
—
—
—
—
—
—
cases:3.23%
controls:2.43%
7
77
252
2513
—
0
5
259
2585
—
—
—
7
53
210
2129
Extensive angiography of hear and/or coronary arteries
FN1BC [2001303000]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
—
0
5
259
2585
—
—
—
—
—
Coeliac disease
K90.0 [45586745]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
cases:0.00%
controls:0.28%
cases:0.00%
controls:0.96%
—
0
11
259
2579
—
—
—
0
7
252
2493
0
21
217
2161
Surface analgesia on skin or mucosa
WX105 [2001310765]
—
-1.0e+50
—
—
—
—
8.1e-01
—
—
cases:0.00%
controls:0.19%
—
—
—
—
—
—
—
—
cases:3.23%
controls:1.47%
—
0
5
259
2585
—
—
—
—
7
32
210
2150
Acute upper respiratory infections of multiple and unspecified sites
J06 [45601116]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.23%
cases:0.00%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
0
6
259
2584
0
5
259
2585
—
—
—
—
—
Dyspnoea
R06.0 [45558449]
4.0e-01
—
—
—
—
—
3.2e-01
cases:4.63%
controls:3.17%
—
—
—
—
—
—
—
—
—
—
cases:5.53%
controls:4.08%
12
82
247
2508
—
—
—
—
—
12
89
205
2093
Acceptance of acknowledgement of paternity of child born outside of marriage before the birth of the child at the maternity clinic. Paternity Act, Section 16.
SPAT1399 [2001700499]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
259
2582
—
—
—
—
—
—
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
G40.2 [45591172]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
259
2585
—
—
—
—
—
—
Orthodontic band in one tooth
SJC10 [2001310432]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
6
217
2176
Metastasis to liver
OMOP5000224 [36770544]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
259
2585
—
—
—
—
—
—
Lump/swelling localized
S04 [2002000969]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
0
10
259
2580
—
—
—
—
—
Chronic gastritis, unspecified
K29.5 [45562484]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
259
2585
—
—
—
—
—
—
fluvoxamine; oral
N06AB08 [21604716]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
259
2584
—
—
—
—
—
—
Acute laryngitis
J04.0 [45533538]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
0
9
217
2173
Cortisol [Moles/volume] in Serum or Plasma
14675-3 [3036481]
—
—
—
—
—
—
7.4e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.69%
controls:1.79%
—
—
—
—
—
—
8
39
209
2143
Type 1 diabetes mellitus, With multiple complications
E10.7 [45571655]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.19%
—
—
—
—
—
—
—
—
0
5
258
2580
—
—
Irritable bowel syndrome with diarrhoea
K58.0 [45596336]
—
—
—
—
—
-1.0e+50
9.9e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
cases:2.30%
controls:0.87%
—
—
—
—
—
0
5
252
2495
5
19
212
2163
Epstein Barr virus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection
43730-1 [3043849]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.31%
cases:0.00%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
0
8
259
2582
0
5
259
2585
—
—
—
—
—
Ileoscopy through colon
UJF30 [2001305028]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
0
6
252
2494
—
Respiratory syncytial virus RNA [Presence] in Specimen by NAA with probe detection
40988-8 [3044254]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.42%
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
0
11
259
2579
0
6
259
2584
—
—
—
—
0
11
217
2171
fludrocortisone and antiinfectives
S02CA07 [21605179]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
0
7
217
2175
Acute subendocardial infarction stenosed coronary artery
I21.41 [2000502433]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
259
2582
—
—
—
—
—
—
Forearm X-ray examination
NC2AA [2001307451]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
0
5
217
2177
Diabetic maculopathy and Type 1 diabetes mellitus, With ophthalmic complications
H36.01*E10.3 [2000503946]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
—
0
5
259
2585
—
—
—
—
—
Stomach Pathology biopsy report
66114-0 [40768797]
8.0e-01
—
-1.0e+50
—
—
—
8.4e-01
cases:3.86%
controls:1.78%
—
—
cases:0.00%
controls:0.19%
—
—
—
—
—
—
cases:5.07%
controls:2.25%
10
46
249
2544
—
0
5
259
2585
—
—
—
11
49
206
2133
dexchlorpheniramine, combinations
R06AB52 [21603467]
9.7e-01
—
—
—
—
—
—
cases:2.32%
controls:0.89%
—
—
—
—
—
—
—
—
—
—
—
—
6
23
253
2567
—
—
—
—
—
—
Hepatitis C virus Ab [Presence] in Serum
16128-1 [3017143]
5.2e-01
1.3e+00
—
—
—
—
8.7e-01
cases:3.09%
controls:1.85%
cases:1.93%
controls:0.54%
—
—
—
—
—
—
—
—
cases:4.15%
controls:1.79%
8
48
251
2542
5
14
254
2576
—
—
—
—
9
39
208
2143
Routine postpartum follow-up
Z39.2 [45547306]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.42%
—
0
7
259
2583
—
—
—
—
0
31
217
2151
Opening and preparing the root canals, extremely complicated
SGA04 [2001310382]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
—
0
11
252
2489
—
FEV1/FVC
19926-5 [3011505]
8.0e-01
—
—
—
—
-1.0e+50
1.5e+00
cases:3.86%
controls:1.78%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
cases:2.76%
controls:0.64%
10
46
249
2544
—
—
—
—
0
6
252
2494
6
14
211
2168
Leukocyte morphology finding [Identifier] in Blood
11156-7 [3008757]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.23%
cases:0.00%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
0
6
259
2584
0
5
259
2585
—
—
—
—
—
Transplant complication
127 [2001600125]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
259
2583
—
—
—
—
—
—
mometasone, combinations
R01AD59 [947911]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
0
16
217
2166
Legionella pneumophila DNA [Presence] in Specimen by NAA with probe detection
21363-7 [3020565]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
0
5
217
2177
Pap smear
SPAT1193 [2001700294]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
0
5
252
2495
—
insulin aspart; parenteral
A10AD05 [21600733]
-2.4e-01
-4.6e-01
—
—
—
-4.0e-01
-8.6e-01
cases:3.09%
controls:3.90%
cases:2.70%
controls:4.21%
—
—
—
—
—
—
cases:3.17%
controls:4.68%
cases:3.23%
controls:7.29%
8
101
251
2489
7
109
252
2481
—
—
—
8
117
244
2383
7
159
210
2023
Preventive oral health care, extensive
SCA03 [2001310304]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
0
10
259
2580
—
—
—
—
—
0
8
217
2174
misoprostol; oral
A02BB01 [21600093]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
0
6
259
2584
—
—
—
—
—
Bacteria identified in Skin by Aerobe culture
620-5 [3007853]
3.4e-01
—
-1.0e+50
—
-1.0e+50
—
6.5e-01
cases:2.32%
controls:1.66%
—
—
cases:0.00%
controls:0.27%
—
—
cases:0.00%
controls:0.39%
—
—
cases:5.07%
controls:2.70%
6
43
253
2547
—
0
7
259
2583
—
0
10
258
2575
—
11
59
206
2123
Paediatric neurology
421 [44777781]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
0
10
259
2580
—
—
—
—
—
donepezil; oral
N06DA02 [21604795]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
0
6
259
2584
—
—
—
—
tramadol and paracetamol
N02AJ13 [1123645]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
259
2582
—
—
—
—
—
—
Back syndrome with radiating pain
L86 [2002000705]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
—
0
5
259
2585
—
—
—
—
—
General psychiatric examination, not elsewhere classified
Z00.4 [45605094]
5.5e-01
—
-1.0e+50
—
—
—
—
cases:1.93%
controls:1.12%
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
5
29
254
2561
—
0
6
259
2584
—
—
—
—
Foot and toes X-ray examination
NH3AA [2001308267]
8.1e-01
—
—
—
—
—
1.2e+00
cases:2.32%
controls:1.04%
—
—
—
—
—
—
—
—
—
—
cases:3.23%
controls:0.96%
6
27
253
2563
—
—
—
—
—
7
21
210
2161
Routine general health check-up of other defined subpopulations
Z10.8 [45609907]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
—
0
5
259
2585
—
—
—
—
—
Unstable angina
I20.09 [2000502389]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
259
2579
—
—
—
—
—
—
Functional dysphonia
R49.01 [2000503597]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
259
2585
—
—
—
—
—
—
paroxetine; oral
N06AB05 [21604713]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
0
6
259
2584
—
—
—
—
—
Protein C actual/normal in Platelet poor plasma by Coagulation assay
27819-2 [3020287]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
259
2585
—
—
—
—
—
—
False labour before 37 completed weeks of gestation
O47.0 [45582556]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
0
6
252
2494
—
Atrial fibrillation/flutter
K78 [2002000605]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
0
9
259
2581
—
—
—
—
—
cefadroxil; oral
J01DB05 [21602874]
6.9e-01
—
—
—
—
—
—
cases:3.47%
controls:1.78%
—
—
—
—
—
—
—
—
—
—
—
—
9
46
250
2544
—
—
—
—
—
—
Alcohol dependence currently independent
F10.20 [2000501677]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
259
2585
—
—
—
—
—
—
Bipolar affective disorder, unspecified
F31.9 [45571758]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
0
8
259
2582
—
—
—
—
—
0
9
217
2173
Joint ultrasound examination not elsewhere classified
NK4XE [2001308469]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
0
9
259
2581
—
—
—
—
—

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
76
394
2.28
7.98
2.6
3.3
3.55
2.50
e6/l
0.34
44
184
41
167
2.71
7.17
2.3
2.5
4.40
19.85
au/ml
—
6
14
38
153
2.72
6.79
1.2
1.3
—
25.74
—
0
13
133
904
1.91
6.45
4.1
4.2
20.38
74.23
e6/l
2.30
97
612
75
429
2.03
5.95
3.8
3.7
148.59
312.84
ng/l
0.57
54
302
111
737
1.85
5.59
3.1
3.1
—
0.25
—
0
8
48
237
2.24
5.53
1.3
1.2
—
—
—
0
0
158
1196
1.75
4.92
6.2
6.8
29.17
29.02
%
0.06
150
1142
137
998
1.74
4.87
2.5
2.0
104.20
97.78
pmol/l
0.78
76
513
154
1174
1.71
4.53
6.2
6.7
56.43
56.39
%
0.02
148
1124
111
778
1.72
4.42
3.5
3.4
22.67
51.51
e6/l
1.17
89
583
152
1163
1.69
4.34
6.4
6.8
0.60
0.69
%
1.52
144
1090
117
837
1.69
4.29
5.1
6.6
—
—
—
0
0
98
675
1.70
4.10
3.3
3.3
0.18
0.42
e6/l
1.23
76
479
152
1174
1.66
4.10
6.4
6.9
8.88
8.59
%
0.69
144
1106
151
1169
1.65
4.00
6.3
6.7
2.76
2.83
%
0.15
144
1096
58
347
1.85
3.91
1.4
1.4
220.00
545.13
titre
3.44
12
78
133
1005
1.63
3.83
5.6
5.4
36.72
36.27
g/l
0.42
127
956
105
751
1.64
3.75
3.3
2.9
—
—
—
0
0
41
223
1.99
3.66
1.7
2.7
31.63
30.06
u/l
0.23
32
183
160
1274
1.61
3.65
5.8
6.7
0.04
0.04
e9/l
0.12
141
1105
162
1297
1.61
3.59
5.9
6.6
1.93
2.00
e9/l
0.27
150
1159
16
57
2.92
3.59
1.5
1.9
—
—
—
0
0
164
1317
1.61
3.58
6.0
7.1
0.20
0.19
e9/l
0.48
149
1160
159
1269
1.60
3.55
5.8
6.7
0.60
0.57
e9/l
0.84
141
1105
85
585
1.66
3.49
2.4
3.2
328.85
334.79
umol/l
0.20
73
521
93
659
1.62
3.38
2.6
2.1
2.39
2.76
mg/l
1.01
80
569
217
1883
1.72
3.35
5.4
4.4
14.28
14.69
pmol/l
1.81
207
1729
173
1423
1.58
3.29
8.1
10.2
4.20
4.00
e9/l
0.66
152
1240
67
440
1.69
3.26
2.7
2.9
512.73
515.33
mosm/kgh2o
0.03
61
387
97
702
1.59
3.21
5.5
4.2
7.39
7.40
ph
0.77
70
492
134
1045
1.55
3.19
8.5
8.0
1.22
1.22
mmol/l
0.66
128
980
158
1281
1.55
3.14
4.8
7.0
9.85
11.35
umol/l
1.88
151
1222
79
548
1.62
3.10
1.8
2.0
1.41
1.51
mg/l
0.08
69
433
144
1147
1.54
3.08
9.5
8.1
1.22
1.21
mmol/l
0.77
130
1013
9
21
4.39
3.02
1.2
2.3
—
—
—
0
0
129
1008
1.53
2.99
24.3
11.9
1.19
1.19
inr
0.02
106
833
21
96
2.29
2.92
2.6
2.4
—
—
—
0
0
92
671
1.56
2.90
2.0
1.7
20.67
20.58
nmol/l
0.02
80
565
74
513
1.61
2.89
2.8
2.7
3.55
7.29
e6/l
1.53
67
471
92
673
1.55
2.85
1.5
1.3
0.85
1.34
u/ml
0.76
11
177
100
749
1.53
2.77
2.4
2.6
55.31
68.84
u/l
0.92
91
698
65
441
1.62
2.76
1.3
1.3
15.31
10.22
u/ml
0.18
18
184
139
1116
1.50
2.76
2.9
2.6
76.46
75.73
nmol/l
0.12
128
1010
84
608
1.55
2.71
1.5
1.4
2.05
2.30
g/l
0.75
45
366
108
826
1.51
2.70
3.6
3.3
2.35
2.36
mmol/l
0.50
96
755
124
982
1.48
2.59
1.9
1.9
1.35
1.33
mmol/l
0.13
111
835
41
253
1.73
2.48
8.0
11.6
0.96
0.85
mmol/l
0.06
32
213
204
1795
1.53
2.44
7.6
8.4
80.19
80.95
u/l
0.06
197
1706
159
1332
1.46
2.43
4.0
3.8
62.04
5.86
estimate
0.42
23
277
153
1278
1.44
2.34
3.8
3.0
92.68
96.87
ug/l
0.15
145
1190
132
1073
1.44
2.34
3.1
3.4
6.37
6.25
ph
0.52
57
583
16
72
2.30
2.32
1.4
1.3
—
—
—
0
0
120
961
1.44
2.29
2.5
2.0
—
—
—
0
0
30
173
1.82
2.28
3.6
3.7
64.74
66.19
g/l
0.47
25
162
41
260
1.68
2.26
8.2
11.3
7.42
7.41
ph
0.38
17
152
33
197
1.77
2.25
4.0
2.2
6.57
6.12
ph
2.26
21
129
159
1345
1.43
2.23
4.2
3.8
0.00
0.01
estimate
0.50
18
256
225
2043
1.56
2.13
23.0
18.5
13.45
13.49
%
0.24
220
2029
10
37
2.77
2.09
1.2
1.2
—
—
—
0
0
35
218
1.69
2.07
1.5
2.6
9.81
10.42
g/l
0.53
30
204
32
195
1.73
2.04
1.3
1.3
177.30
131.25
u/ml
—
10
79
82
623
1.45
2.04
4.7
4.1
—
—
—
0
0
34
211
1.70
2.03
7.4
11.9
—
—
—
0
0
19
98
2.01
2.00
1.7
1.8
—
—
—
0
0
155
1323
1.39
1.96
3.8
3.7
0.00
0.00
estimate
-0.00
22
278
6
16
3.81
1.94
1.0
1.1
—
—
—
0
0
51
357
1.53
1.88
1.8
1.6
885.76
1223.77
nmol/l
2.78
36
272
40
265
1.60
1.87
1.3
1.3
—
—
—
0
0
162
1400
1.38
1.87
5.8
5.8
6.49
6.50
mmol/l
0.02
154
1312
94
745
1.40
1.83
6.7
7.2
—
—
—
0
0
20
109
1.90
1.82
2.1
1.8
—
—
—
0
0
184
1628
1.39
1.81
3.5
3.5
38.89
42.58
u/l
0.37
177
1552
25
147
1.77
1.81
4.7
4.0
4.43
4.63
pmol/l
0.67
25
130
64
477
1.45
1.74
1.5
1.3
13.16
29.28
iu/ml
2.58
23
155
25
149
1.75
1.74
1.4
1.3
—
—
—
0
0
14
68
2.12
1.73
1.4
2.3
—
—
—
0
0
11
48
2.35
1.73
1.2
1.1
—
—
—
0
0
11
48
2.35
1.73
1.2
1.1
—
—
—
0
0
15
76
2.03
1.68
1.1
1.2
—
—
—
0
0
23
137
1.74
1.61
1.4
3.0
—
—
—
0
0
8
32
2.54
1.61
2.0
2.6
—
—
—
0
0
7
26
2.74
1.59
1.4
1.3
—
—
—
0
0
238
2224
1.52
1.58
6.8
5.4
1.79
1.88
mu/l
0.75
228
2068
12
57
2.16
1.57
3.3
3.0
0.00
1.77
index
—
5
35
135
1157
1.33
1.53
2.9
2.9
—
—
estimate
—
0
0
78
617
1.37
1.50
2.3
2.1
—
—
—
0
0
11
55
2.04
1.29
4.4
3.1
28.55
32.80
umol/l
0.43
11
50
226
2117
1.38
1.23
6.5
6.1
37.86
38.82
mmol/mol
1.03
218
2003
72
580
1.33
1.22
3.6
3.7
1.02
1.02
kg/l
0.44
50
374
42
311
1.41
1.20
1.4
1.2
—
—
—
0
0
8
38
2.14
1.19
1.3
1.2
—
—
—
0
0
23
151
1.57
1.16
5.8
5.7
23.91
24.19
mmol/l
0.17
23
151
255
2448
1.57
1.14
12.6
11.9
25.08
26.16
u/l
0.53
250
2397
10
51
2.00
1.12
1.1
2.0
—
—
—
0
0
246
2348
1.45
1.10
23.0
17.6
3.95
3.96
mmol/l
0.15
241
2307
248
2371
1.47
1.09
21.0
14.9
24.62
22.79
mg/l
0.35
203
1899
56
444
1.33
1.06
1.9
1.8
147917058.46
446.63
pmol/l
0.49
48
376
7
35
2.03
1.00
1.0
1.5
0.37
0.49
nmol/l
—
7
30
7
36
1.97
0.97
1.0
1.1
—
—
—
0
0
6
28
2.17
0.92
1.0
1.2
—
—
—
0
0
56
455
1.29
0.90
2.1
2.4
2.42
2.44
mmol/l
0.57
44
413
15
95
1.61
0.89
1.4
2.2
1.45
1.46
g/l
0.02
15
85
39
302
1.34
0.87
1.4
1.5
—
—
—
0
0
17
112
1.55
0.87
1.1
1.1
—
—
—
0
0
13
80
1.66
0.86
1.1
1.2
—
76.36
—
0
11
19
129
1.51
0.86
1.5
1.8
—
—
—
0
0
33
250
1.36
0.85
5.3
5.1
7.35
7.39
ph
2.45
22
154
6
31
1.96
0.85
1.0
1.2
—
—
—
0
0
12
73
1.67
0.83
1.9
2.0
22.68
23.95
mmol/l
0.49
12
73
92
801
1.22
0.82
3.6
3.5
7.91
7.70
mmol/l
0.17
78
679
69
583
1.25
0.81
4.5
4.5
92.72
92.48
%
0.03
69
577
16
106
1.54
0.81
1.3
1.2
—
—
—
0
0
27
200
1.39
0.80
11.9
9.0
11.49
9.11
mmol/l
0.46
27
193
0
25
0.00
0.79
0.0
1.2
—
—
—
0
0
33
254
1.34
0.78
1.2
1.4
—
—
—
0
0
7
38
1.86
0.74
2.4
2.1
—
—
—
0
0
224
2141
1.25
0.71
4.2
4.1
1.27
1.25
mmol/l
0.10
215
1986
5
26
1.94
0.71
1.6
2.7
—
—
—
0
0
42
340
1.28
0.71
2.0
1.6
—
—
—
0
0
7
41
1.73
0.70
1.0
1.1
—
—
—
0
0
37
295
1.29
0.70
3.0
1.6
—
—
—
0
0
14
202
0.68
0.68
4.6
3.5
—
—
—
0
0
29
224
1.33
0.68
3.3
2.0
0.00
0.00
estimate
—
5
52
12
78
1.56
0.66
12.6
9.4
—
—
—
0
0
7
44
1.61
0.65
1.1
1.7
—
—
—
0
0
61
521
1.22
0.65
1.8
1.7
—
—
—
0
0
0
20
0.00
0.60
0.0
1.2
—
—
—
0
0
83
930
0.85
0.60
3.1
3.1
—
—
—
0
0
19
140
1.38
0.60
1.2
1.4
0.31
0.30
mg/l
0.05
12
55
22
167
1.34
0.59
7.5
10.5
24.85
24.83
mmol/l
0.01
22
167
123
1131
1.16
0.56
8.7
11.0
0.00
0.00
e9/l
0.33
94
924
11
74
1.51
0.54
1.3
1.3
—
—
—
0
0
88
792
1.16
0.53
2.4
2.4
—
—
—
0
0
41
344
1.23
0.53
3.4
2.1
—
—
—
0
0
17
126
1.37
0.53
5.3
9.0
—
—
—
0
0
79
707
1.16
0.51
3.9
3.5
77.27
73.98
mg/l
0.03
55
455
30
244
1.26
0.51
4.9
5.1
1.37
1.64
mmol/l
0.14
23
207
38
318
1.23
0.50
7.8
7.6
104.08
104.31
mmol/l
0.12
38
318
62
547
1.17
0.48
6.4
5.3
2.17
1.93
ug/l
0.26
57
483
232
2252
1.19
0.46
5.1
4.8
1.51
1.49
mmol/l
0.34
221
2097
44
378
1.20
0.46
2.4
2.3
48.11
111.78
ug/g
3.06
38
299
233
2263
1.19
0.45
5.2
4.9
4.75
4.65
mmol/l
0.79
224
2124
11
78
1.43
0.44
1.6
1.4
325.50
327.33
ug/g
—
6
44
5
31
1.62
0.43
1.2
1.5
21.56
34.75
ng/l
—
5
31
0
15
0.00
0.41
0.0
2.3
—
0.87
—
0
15
0
15
0.00
0.41
0.0
3.1
—
666.50
—
0
6
235
2289
1.18
0.41
6.1
5.4
2.77
2.72
mmol/l
0.37
225
2136
24
198
1.23
0.38
4.7
4.6
7.29
7.35
ph
0.42
19
143
5
37
1.36
0.37
1.8
1.8
—
—
—
0
0
5
37
1.36
0.37
1.8
1.8
—
—
—
0
0
5
37
1.36
0.37
1.8
1.8
—
—
—
0
0
5
37
1.36
0.37
1.8
1.8
—
—
—
0
0
21
171
1.25
0.37
1.3
1.3
—
—
—
0
0
227
2213
1.15
0.34
5.0
4.8
5.79
5.81
mmol/l
0.13
215
2045
66
719
0.89
0.32
4.1
3.7
0.00
0.01
estimate
0.74
21
259
92
859
1.11
0.31
4.1
3.9
102.86
103.04
ng/l
0.00
49
586
35
307
1.16
0.30
1.2
1.3
—
—
—
0
0
25
215
1.18
0.28
1.7
1.5
—
—
—
0
0
77
718
1.10
0.26
4.3
4.2
16.76
12.63
mg/mmol
0.21
49
450
36
321
1.14
0.26
3.1
3.0
0.77
0.76
ug/l
0.02
24
207
248
2443
1.15
0.25
16.1
12.9
—
—
—
0
0
13
106
1.24
0.23
1.6
1.4
155.89
281.05
miu/ml
—
8
55
16
134
1.21
0.23
1.3
1.1
—
—
—
0
0
5
39
1.29
0.23
1.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
3.97
—
0
11
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
27.40
—
0
10
0
10
0.00
0.21
0.0
1.5
—
58.60
—
0
10
0
10
0.00
0.21
0.0
1.1
—
171.07
—
0
10
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
11
89
1.25
0.21
1.3
1.5
—
—
—
0
0
0
13
0.00
0.21
0.0
3.2
—
501.67
—
0
6
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
13
108
1.21
0.20
1.3
1.5
—
—
—
0
0
0
14
0.00
0.20
0.0
1.5
—
16.83
—
0
14
0
14
0.00
0.20
0.0
1.3
—
186.71
—
0
14
18
206
0.86
0.19
1.5
1.7
685.28
935.37
mu/l
0.86
12
185
24
214
1.13
0.18
1.7
1.8
3.45
3.47
mmol/l
0.03
18
158
11
92
1.20
0.16
1.4
1.6
—
—
—
0
0
38
352
1.09
0.16
1.9
1.6
—
—
—
0
0
14
121
1.17
0.15
5.7
6.3
—
—
—
0
0
7
89
0.78
0.14
3.0
7.5
1.90
1.30
mg/l
—
7
81
16
141
1.14
0.14
5.3
2.5
33.25
45.54
u/ml
0.27
16
135
103
996
1.05
0.13
3.7
3.5
0.00
0.02
estimate
0.78
16
231
15
132
1.14
0.13
2.1
1.5
—
—
—
0
0
77
741
1.05
0.12
3.5
3.2
0.00
0.00
estimate
-0.00
17
227
5
46
1.09
0.09
2.4
1.8
6.28
6.87
pmol/l
—
5
46
12
108
1.12
0.07
1.1
3.1
20.83
21.82
s
0.48
12
100
9
86
1.05
0.07
2.0
1.9
0.65
4.22
ug/l
—
9
78
22
207
1.07
0.06
1.6
3.6
58.68
72.19
e9/l
1.63
12
151
79
773
1.03
0.05
1.6
1.6
—
—
—
0
0
39
376
1.04
0.05
1.9
1.8
—
—
—
0
0
22
229
0.96
0.03
1.9
4.5
2.48
35.46
ug/l
0.58
15
191
61
600
1.02
0.02
2.9
4.8
—
—
—
0
0
14
147
0.95
0.01
2.1
1.5
—
—
—
0
0
11
104
1.06
0.01
3.8
4.9
36.87
36.94
°c
0.24
11
104
13
124
1.05
0.00
2.8
2.0
0.00
0.00
estimate
—
6
44
15
144
1.04
0.00
2.1
1.5
—
—
—
0
0
20
199
1.01
0.00
1.3
1.5
—
—
—
0
0
15
145
1.04
0.00
2.1
1.5
—
—
—
0
0
14
144
0.97
0.00
2.1
1.5
—
—
—
0
0
0
6
0.00
0.00
0.0
2.3
—
26.33
—
0
6
0
6
0.00
0.00
0.0
1.2
—
1.21
—
0
6
0
6
0.00
0.00
0.0
5.0
—
1.98
—
0
6
0
6
0.00
0.00
0.0
4.8
—
42.17
—
0
6
0
6
0.00
0.00
0.0
6.5
—
3.06
—
0
6
0
6
0.00
0.00
0.0
9.8
—
8.04
—
0
6
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
2.61
—
0
6
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
8
83
0.96
-0.00
1.1
1.1
1.51
1.58
g/l
—
8
83
8
85
0.94
-0.00
1.1
1.2
0.75
0.89
g/l
—
8
85
0
5
0.00
-0.00
0.0
1.6
—
11.32
—
0
5
7
75
0.93
-0.00
1.3
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
28.6
—
149.40
—
0
5
7
70
1.00
-0.00
1.1
2.1
12.49
11.42
mg/l
—
7
65
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
60.60
—
0
5
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
5.6
—
16.38
—
0
5
0
7
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
154.33
—
0
9
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
6
62
0.97
-0.00
2.5
1.8
—
—
—
0
0

Mortality – FinRegistry

↥

Association

Association between endpoint INCREASEDMUSCLETONE and mortality.

Females

Parameter HR [95% CI] p-value
INCREASEDMUSCLETONE 1.498 [1.12, 2.01] 0.006
Birth year 0.997 [0.99, 1.01] 0.455

During the follow-up period (1.1.1998 — 31.12.2019), 93 out of 1243 females with INCREASEDMUSCLETONE died.

Males

Parameter HR [95% CI] p-value
INCREASEDMUSCLETONE 1.505 [1.12, 2.02] 0.006
Birth year 0.987 [0.98, 1.0] 0.007

During the follow-up period (1.1.1998 — 31.12.2019), 122 out of 1128 males with INCREASEDMUSCLETONE died.

Mortality risk

Mortality risk for people of age

years, who have INCREASEDMUSCLETONE.

N-year risk Females Males
1 0.187% 0.339%
5 0.974% 1.718%
10 2.335% 4.324%
15 4.498% 8.337%
20 7.859% 13.408%

Relationships between endpoints

↥

Index endpoint: INCREASEDMUSCLETONE – Increased muscle tone

GWS hits: 1

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data